<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS Xcelerate Instance Document - http://www.dfsco.com/financial-services/ -->
<!-- Version:  6.23.6 -->
<!-- Round: 3 -->
<!-- Creation date: 2017-05-06T14:15:46Z -->
<!-- Copyright (c) 2017 Donnelley Financial, LLC. All Rights Reserved. -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2016-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:sndx="http://www.syndax.com/20170331" xmlns:us-types="http://fasb.org/us-types/2016-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:country="http://xbrl.sec.gov/country/2016-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2016-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2016-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:utr="http://www.xbrl.org/2009/utr">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="sndx-20170331.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <sndx:PotentialMilestonePaymentsReceivable contextRef="eol_PE740721--1710-Q0002_STD_0_20141219_0_2025578x2156357_2028497x2033371_2036820x2089060" unitRef="iso4217_USD" decimals="INF" id="id_10801076_BA383A0A-AEF8-42AE-B32F-A6CB4362E2DF_2001_2">75000000</sndx:PotentialMilestonePaymentsReceivable>
  <sndx:UpfrontPaymentAllocatedToLicenseFee contextRef="eol_PE740721--1710-Q0002_STD_0_20141219_0_2025578x2156357_2036820x2089060" unitRef="iso4217_USD" decimals="-5" id="id_10801076_9F730D69-4630-4489-8ABF-CA04B4C14AED_1001_2">17300000</sndx:UpfrontPaymentAllocatedToLicenseFee>
  <sndx:UpfrontPaymentsReceived contextRef="eol_PE740721--1710-Q0002_STD_0_20141219_0_2025578x2156357_2036820x2089060" unitRef="iso4217_USD" decimals="-5" id="id_10801076_BA383A0A-AEF8-42AE-B32F-A6CB4362E2DF_3001_0">25000000</sndx:UpfrontPaymentsReceived>
  <us-gaap:PreferredStockValue contextRef="eol_PE740721--1710-Q0002_STD_0_20141219_0_2025578x2156357_2036820x2089060_2039549x2309240" unitRef="iso4217_USD" decimals="-5" id="id_10801076_9F730D69-4630-4489-8ABF-CA04B4C14AED_2001_1">7700000</us-gaap:PreferredStockValue>
  <us-gaap:PreferredStockSharesIssued contextRef="eol_PE740721--1710-Q0002_STD_0_20141219_0_2025578x2156357_2036820x2089060_2039549x2309240" unitRef="shares" decimals="INF" id="id_10801076_BA383A0A-AEF8-42AE-B32F-A6CB4362E2DF_4001_1">536049</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockRedemptionAmount contextRef="eol_PE740721--1710-Q0002_STD_0_20150131_0_2025578x2156357_2036820x2089060_2039549x2309240" unitRef="iso4217_USD" decimals="-5" id="id_10801076_9F730D69-4630-4489-8ABF-CA04B4C14AED_4002_5">5400000</us-gaap:PreferredStockRedemptionAmount>
  <us-gaap:SharePrice contextRef="eol_PE740721--1710-Q0002_STD_0_20150131_0_2025578x2156357_2036820x2089060_2039549x2309240" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_10801076_9F730D69-4630-4489-8ABF-CA04B4C14AED_4002_0">14.39</us-gaap:SharePrice>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="eol_PE740721--1710-Q0002_STD_0_20151031_0_2033594x2167040" unitRef="iso4217_USD" decimals="-5" id="id_10801076_9B6C53C6-E336-4ABD-8836-EE314FB70E68_2002_1">100000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <sndx:PotentialMilestonePaymentsUponAchievementOfMilestone contextRef="eol_PE740721--1710-Q0002_STD_0_20160731_0_2025578x2398884_2036820x2398883" unitRef="iso4217_USD" decimals="-5" id="id_10801076_5682B65B-8D38-4A34-8705-E796A37CAC5D_2002_1">119500000</sndx:PotentialMilestonePaymentsUponAchievementOfMilestone>
  <sndx:AggregatePotentialMilestonePayable contextRef="eol_PE740721--1710-Q0002_STD_0_20160731_0_2025578x2398884_2036820x2398883" unitRef="iso4217_USD" decimals="-5" id="id_10801076_5682B65B-8D38-4A34-8705-E796A37CAC5D_2002_2">250000000</sndx:AggregatePotentialMilestonePayable>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE740721--1710-Q0002_STD_0_20170131_0_2028497x2033371_2029102x2256568" unitRef="shares" decimals="INF" id="id_10801076_5838BB31-648A-4A59-9E2B-35CD238F0844_1001_0">728948</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE740721--1710-Q0002_STD_0_20170131_0_2029102x2084902" unitRef="shares" decimals="INF" id="id_10801076_AA09AB07-6F5B-4847-A389-E62E8DCD8FB8_1001_0">182237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <dei:EntityCommonStockSharesOutstanding contextRef="eol_PE740721--1710-Q0002_STD_0_20170502_0" unitRef="shares" decimals="INF" id="id_10801076_2B8770BA-C548-4409-843A-5A64E6BDAD1E_2_5">18255943</dei:EntityCommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE740721--1710-Q0002_STD_0_20170505_0_2037362x2039759" unitRef="shares" decimals="INF" id="id_10801076_457D94D4-6629-4FBE-B009-194DACFEEC58_3002_1">0</us-gaap:CommonStockSharesIssued>
  <us-gaap:ContractualObligation contextRef="eol_PE740721--1710-Q0002_STD_0_20070331_0_2025578x2125274_2028497x2033371_2036820x2089060" unitRef="iso4217_USD" decimals="INF" id="id_10801076_14391EA3-4240-40C7-9279-17B664A30DAF_2001_2">150000000</us-gaap:ContractualObligation>
  <us-gaap:DeferredOfferingCosts contextRef="eol_PE740721--1710-Q0002_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-5" id="id_10801076_B218FA78-5280-45E0-B6B5-0679E6BFBC21_2_0">0</us-gaap:DeferredOfferingCosts>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE740721--1710-Q0002_STD_0_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1002_26">23187000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <sndx:CostsRelatedToCostSharingCollaborations contextRef="eol_PE740721--1710-Q0002_STD_0_20160331_0_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_10801076_3B52685B-79CF-420E-BFEC-4842EDA8C109_2002_0">0</sndx:CostsRelatedToCostSharingCollaborations>
  <us-gaap:CommonStockSharesIssued contextRef="eol_PE740721--1710-Q0002_STD_0_20160331_0_2040137x2029877" unitRef="shares" decimals="INF" id="id_10801076_1A7D9B18-E2E1-4374-9101-8F16C00FE43C_3001_0">4809475</us-gaap:CommonStockSharesIssued>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="eol_PE740721--1710-Q0002_STD_0_20160331_0_2040137x2029877" unitRef="shares" decimals="INF" id="id_10801076_1A7D9B18-E2E1-4374-9101-8F16C00FE43C_3001_6">357840</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:SharesIssuedPricePerShare contextRef="eol_PE740721--1710-Q0002_STD_0_20160331_0_2040137x2029877" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_10801076_1A7D9B18-E2E1-4374-9101-8F16C00FE43C_3001_1">12.00</us-gaap:SharesIssuedPricePerShare>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="eol_PE740721--1710-Q0002_STD_0_20160331_0_2040137x2029877" unitRef="shares" decimals="INF" id="id_10801076_1A7D9B18-E2E1-4374-9101-8F16C00FE43C_3001_5">12872551</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_10801076_86F651C6-49CD-462E-BDA5-0BF4FD693C3E_1_3">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_21" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="shares" decimals="INF" id="id_10801076_86F651C6-49CD-462E-BDA5-0BF4FD693C3E_1_5">18244917</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:Assets contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_9">97667000</us-gaap:Assets>
  <us-gaap:DeferredOfferingCosts contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-5" id="id_10801076_B218FA78-5280-45E0-B6B5-0679E6BFBC21_1_0">100000</us-gaap:DeferredOfferingCosts>
  <us-gaap:AssetsCurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_6">97057000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1003_2">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1003_3">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="shares" decimals="INF" id="id_10801076_86F651C6-49CD-462E-BDA5-0BF4FD693C3E_1_4">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1003_4">70429000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_25">390894000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_2">22356000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockValue contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_24">2000</us-gaap:CommonStockValue>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_17">13915000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1003_1">70431000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_12">2741000</us-gaap:AccountsPayableCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_14">1220000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DepositsAssetsCurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_389F3895-906D-4AB7-83E0-54F275719692_1_0">2419000</us-gaap:DepositsAssetsCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_26">-2000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_13">7028000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_10801076_86F651C6-49CD-462E-BDA5-0BF4FD693C3E_1_0">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:OtherPrepaidExpenseCurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_389F3895-906D-4AB7-83E0-54F275719692_1_5">220000</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="shares" decimals="INF" id="id_10801076_86F651C6-49CD-462E-BDA5-0BF4FD693C3E_1_1">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:InterestReceivableCurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_389F3895-906D-4AB7-83E0-54F275719692_1_2">210000</us-gaap:InterestReceivableCurrent>
  <us-gaap:PrepaidInsurance contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_389F3895-906D-4AB7-83E0-54F275719692_1_1">637000</us-gaap:PrepaidInsurance>
  <us-gaap:LiabilitiesNoncurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_19">14063000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="shares" decimals="INF" id="id_10801076_86F651C6-49CD-462E-BDA5-0BF4FD693C3E_1_2">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:Liabilities contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_20">25052000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_29">97667000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_18">148000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_15">10989000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_8">376000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" xsi:nil="true" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_23" />
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_7">234000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ShortTermInvestments contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_4">70429000</us-gaap:ShortTermInvestments>
  <us-gaap:StockholdersEquity contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_28">72615000</us-gaap:StockholdersEquity>
  <us-gaap:Supplies contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_389F3895-906D-4AB7-83E0-54F275719692_1_4">310000</us-gaap:Supplies>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_27">-318279000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_5">4170000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_1_3">102000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <sndx:ReimbursableCosts contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_389F3895-906D-4AB7-83E0-54F275719692_1_3">374000</sndx:ReimbursableCosts>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2022410x2021995" unitRef="iso4217_USD" decimals="-3" id="id_10801076_0F52CCC5-65D9-4BFE-BF1B-F3F3C771A771_2003_1">3446000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2022410x2021995" unitRef="iso4217_USD" decimals="-3" id="id_10801076_0F52CCC5-65D9-4BFE-BF1B-F3F3C771A771_2003_3">73875000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:ShortTermInvestments contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2022410x2021995" unitRef="iso4217_USD" decimals="-3" id="id_10801076_0F52CCC5-65D9-4BFE-BF1B-F3F3C771A771_2003_2">70429000</us-gaap:ShortTermInvestments>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2022410x2021995_2031210x2024283" unitRef="iso4217_USD" decimals="-5" id="id_10801076_486607F6-448D-4274-8676-3E47D1894FB1_1001_1">3400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2022410x2021995_2031210x2323317" unitRef="iso4217_USD" decimals="-5" id="id_10801076_76EC396C-DD0F-41DB-8851-C3653665C47C_1001_0">70400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2022410x2026970" unitRef="iso4217_USD" decimals="-3" id="id_10801076_0F52CCC5-65D9-4BFE-BF1B-F3F3C771A771_2002_1">18910000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2022410x2026970" unitRef="iso4217_USD" decimals="-3" id="id_10801076_0F52CCC5-65D9-4BFE-BF1B-F3F3C771A771_2002_3">18910000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2022410x2026970_2025340x2428344" unitRef="iso4217_USD" decimals="-5" id="id_10801076_486607F6-448D-4274-8676-3E47D1894FB1_2001_0">18900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2022642x2026006" unitRef="iso4217_USD" decimals="-3" id="id_10801076_0F52CCC5-65D9-4BFE-BF1B-F3F3C771A771_2001_1">22356000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2022642x2026006" unitRef="iso4217_USD" decimals="-3" id="id_10801076_0F52CCC5-65D9-4BFE-BF1B-F3F3C771A771_2001_3">92785000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:ShortTermInvestments contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2022642x2026006" unitRef="iso4217_USD" decimals="-3" id="id_10801076_0F52CCC5-65D9-4BFE-BF1B-F3F3C771A771_2001_2">70429000</us-gaap:ShortTermInvestments>
  <us-gaap:OtherLongTermDebtNoncurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2023370x2394104_2033594x2167040_2040137x2029877" unitRef="iso4217_USD" decimals="-5" id="id_10801076_9B6C53C6-E336-4ABD-8836-EE314FB70E68_1001_0">200000</us-gaap:OtherLongTermDebtNoncurrent>
  <us-gaap:ContractualObligation contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2025578x2046871_2036820x2218844" unitRef="iso4217_USD" decimals="-5" id="id_10801076_AE3C9D1C-1B02-415E-992B-9DC830F05A7C_2001_1">23400000</us-gaap:ContractualObligation>
  <sndx:RemainingContractualObligation contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2025578x2046871_2036820x2218844" unitRef="iso4217_USD" decimals="-5" id="id_10801076_AE3C9D1C-1B02-415E-992B-9DC830F05A7C_2001_2">14900000</sndx:RemainingContractualObligation>
  <us-gaap:DeferredRevenue contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2025578x2156357_2036820x2089060" unitRef="iso4217_USD" decimals="-5" id="id_10801076_425221EA-975B-4628-BF90-44D7B870EBED_2001_1">15100000</us-gaap:DeferredRevenue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2029102x2084902" unitRef="shares" decimals="INF" id="id_10801076_AA09AB07-6F5B-4847-A389-E62E8DCD8FB8_1002_0">432237</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2029102x2256568" unitRef="shares" decimals="INF" id="id_10801076_5838BB31-648A-4A59-9E2B-35CD238F0844_2002_1">1578921</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2029102x2429960" unitRef="iso4217_USD" decimals="-5" id="id_10801076_188E48DE-CC04-459A-B7A7-D2079E484E8B_2001_0">10700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2031210x2024283" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1002_2">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2031210x2024283" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1002_3">23000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2031210x2024283" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1002_4">43978000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2031210x2024283" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1002_1">44001000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2031210x2026209" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1001_2">21000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2031210x2026209" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1001_4">26451000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2031210x2026209" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1001_1">26430000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <sndx:CostsRelatedToCostSharingCollaborations contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_10801076_3B52685B-79CF-420E-BFEC-4842EDA8C109_2001_0">400000</sndx:CostsRelatedToCostSharingCollaborations>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2040137x2029877" unitRef="shares" decimals="INF" id="id_10801076_B888F7F8-C78B-4E34-8C44-4237606C7FD4_1001_0">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE740721--1710-Q0002_STD_0_20170331_0_2040137x2029877" unitRef="shares" decimals="INF" id="id_10801076_B888F7F8-C78B-4E34-8C44-4237606C7FD4_1001_1">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE740721--1710-Q0002_STD_0_20151231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2001_25">23179000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockParOrStatedValuePerShare contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_10801076_86F651C6-49CD-462E-BDA5-0BF4FD693C3E_2_3">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommitmentsAndContingencies contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_21" />
  <us-gaap:CommonStockSharesOutstanding contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_10801076_86F651C6-49CD-462E-BDA5-0BF4FD693C3E_2_5">18215181</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:Assets contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_9">109013000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_6">108510000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1006_2">67000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1006_3">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:CommonStockSharesAuthorized contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_10801076_86F651C6-49CD-462E-BDA5-0BF4FD693C3E_2_4">100000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1006_4">81486000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_25">389374000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_2">23844000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CommonStockValue contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_24">2000</us-gaap:CommonStockValue>
  <us-gaap:DeferredRevenueNoncurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_17">14220000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1006_1">81430000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AccountsPayableCurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_12">2375000</us-gaap:AccountsPayableCurrent>
  <us-gaap:DeferredRevenueCurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_14">1220000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DepositsAssetsCurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_389F3895-906D-4AB7-83E0-54F275719692_2_0">1630000</us-gaap:DepositsAssetsCurrent>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_26">56000</us-gaap:AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
  <us-gaap:AccruedLiabilitiesAndOtherLiabilities contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_13">6771000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
  <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_10801076_86F651C6-49CD-462E-BDA5-0BF4FD693C3E_2_0">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
  <us-gaap:OtherPrepaidExpenseCurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_389F3895-906D-4AB7-83E0-54F275719692_2_5">202000</us-gaap:OtherPrepaidExpenseCurrent>
  <us-gaap:PreferredStockSharesAuthorized contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_10801076_86F651C6-49CD-462E-BDA5-0BF4FD693C3E_2_1">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:InterestReceivableCurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_389F3895-906D-4AB7-83E0-54F275719692_2_2">306000</us-gaap:InterestReceivableCurrent>
  <us-gaap:PrepaidInsurance contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_389F3895-906D-4AB7-83E0-54F275719692_2_1">168000</us-gaap:PrepaidInsurance>
  <us-gaap:LiabilitiesNoncurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_19">14508000</us-gaap:LiabilitiesNoncurrent>
  <us-gaap:PreferredStockSharesOutstanding contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="shares" decimals="INF" id="id_10801076_86F651C6-49CD-462E-BDA5-0BF4FD693C3E_2_2">0</us-gaap:PreferredStockSharesOutstanding>
  <us-gaap:Liabilities contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_20">24874000</us-gaap:Liabilities>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_29">109013000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:OtherLiabilitiesNoncurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_18">288000</us-gaap:OtherLiabilitiesNoncurrent>
  <us-gaap:LiabilitiesCurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_15">10366000</us-gaap:LiabilitiesCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_8">243000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PreferredStockValue contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" xsi:nil="true" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_23" />
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_7">260000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ShortTermInvestments contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_4">81486000</us-gaap:ShortTermInvestments>
  <us-gaap:StockholdersEquity contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_28">84139000</us-gaap:StockholdersEquity>
  <us-gaap:Supplies contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_389F3895-906D-4AB7-83E0-54F275719692_2_4">461000</us-gaap:Supplies>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_27">-305293000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_5">3029000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_48E58EA7-620D-478F-A043-C76D1C1CD2CC_2_3">151000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
  <sndx:ReimbursableCosts contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_389F3895-906D-4AB7-83E0-54F275719692_2_3">262000</sndx:ReimbursableCosts>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022410x2021995" unitRef="iso4217_USD" decimals="-3" id="id_10801076_0F52CCC5-65D9-4BFE-BF1B-F3F3C771A771_1003_4">6755000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022410x2021995" unitRef="iso4217_USD" decimals="-3" id="id_10801076_0F52CCC5-65D9-4BFE-BF1B-F3F3C771A771_1003_6">88241000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:ShortTermInvestments contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022410x2021995" unitRef="iso4217_USD" decimals="-3" id="id_10801076_0F52CCC5-65D9-4BFE-BF1B-F3F3C771A771_1003_5">81486000</us-gaap:ShortTermInvestments>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022410x2021995_2031210x2024283" unitRef="iso4217_USD" decimals="-5" id="id_10801076_486607F6-448D-4274-8676-3E47D1894FB1_1002_1">6800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022410x2021995_2031210x2323317" unitRef="iso4217_USD" decimals="-5" id="id_10801076_76EC396C-DD0F-41DB-8851-C3653665C47C_1002_0">81500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:WarrantsAndRightsOutstanding contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022410x2022419_2026789x2263464" unitRef="iso4217_USD" decimals="-3" id="id_10801076_2686C1B3-CB33-4DA4-BA82-268874340CB9_1001_1">2848000</us-gaap:WarrantsAndRightsOutstanding>
  <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022410x2022419_2027829x2026079" unitRef="iso4217_USD" decimals="-3" id="id_10801076_464B2606-0840-4D5E-AEB8-E159A5822F1A_1001_1">133000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022410x2026970" unitRef="iso4217_USD" decimals="-3" id="id_10801076_0F52CCC5-65D9-4BFE-BF1B-F3F3C771A771_1002_4">17089000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022410x2026970" unitRef="iso4217_USD" decimals="-3" id="id_10801076_0F52CCC5-65D9-4BFE-BF1B-F3F3C771A771_1002_6">17089000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022410x2026970_2025340x2428344" unitRef="iso4217_USD" decimals="-5" id="id_10801076_486607F6-448D-4274-8676-3E47D1894FB1_2002_0">17100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022642x2026006" unitRef="iso4217_USD" decimals="-3" id="id_10801076_0F52CCC5-65D9-4BFE-BF1B-F3F3C771A771_1001_4">23844000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022642x2026006" unitRef="iso4217_USD" decimals="-3" id="id_10801076_0F52CCC5-65D9-4BFE-BF1B-F3F3C771A771_1001_6">105330000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:ShortTermInvestments contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022642x2026006" unitRef="iso4217_USD" decimals="-3" id="id_10801076_0F52CCC5-65D9-4BFE-BF1B-F3F3C771A771_1001_5">81486000</us-gaap:ShortTermInvestments>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2025578x2125274_2036820x2089060" unitRef="iso4217_USD_per_shares" decimals="INF" id="id_10801076_B437BD88-73B3-4512-B71D-74AC55E7F472_2001_2">1.54</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2031210x2024283" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1005_2">6000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2031210x2024283" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1005_3">11000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2031210x2024283" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1005_4">51300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2031210x2024283" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1005_1">51305000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2031210x2026209" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1004_2">61000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2031210x2026209" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1004_4">30186000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="eol_PE740721--1710-Q0002_STD_0_20161231_0_2031210x2026209" unitRef="iso4217_USD" decimals="-3" id="id_10801076_53BA4927-643F-4DD4-8EC8-86ECA06AC413_1004_1">30125000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
  <sndx:PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct contextRef="eol_PE740721--1710-Q0002_STD_1_20141219_0_2025578x2156357_2036820x2089060" id="id_10801076_BA383A0A-AEF8-42AE-B32F-A6CB4362E2DF_1001_3">P15Y</sndx:PeriodOfTerminationAfterFirstCommercialSaleOfFirstLicensedProduct>
  <sndx:PaymentSpecifiedPercentageOfGrossProceedsFromSaleOfShares contextRef="eol_PE740721--1710-Q0002_STD_1_20170505_0_2037362x2039759" unitRef="pure" decimals="INF" id="id_10801076_457D94D4-6629-4FBE-B009-194DACFEEC58_2002_2">0.03</sndx:PaymentSpecifiedPercentageOfGrossProceedsFromSaleOfShares>
  <sndx:NumberOfExecutivesOptionsVested contextRef="eol_PE740721--1710-Q0002_STD_1_20170308_0_2040137x2029877" unitRef="Executives" decimals="INF" id="id_10801076_5BEDBFB7-1983-493A-93E2-34D24CFD397B_1001_0">2</sndx:NumberOfExecutivesOptionsVested>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="eol_PE740721--1710-Q0002_STD_1_20170406_0_2033330x2370882_2037362x2039759_2039870x2428472" unitRef="iso4217_USD" decimals="-5" id="id_10801076_457D94D4-6629-4FBE-B009-194DACFEEC58_1001_0">50000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE740721--1710-Q0002_STD_27_20140630_0_2025578x2125274_2036820x2089060" unitRef="iso4217_USD" decimals="-5" id="id_10801076_14391EA3-4240-40C7-9279-17B664A30DAF_1003_1">2000000</us-gaap:ResearchAndDevelopmentExpense>
  <sndx:NonRefundableUpFrontPaymentReceived contextRef="eol_PE740721--1710-Q0002_STD_28_20150228_0_2025578x2156357_2036820x2089060" unitRef="iso4217_USD" decimals="-5" id="id_10801076_9F730D69-4630-4489-8ABF-CA04B4C14AED_1003_3">17500000</sndx:NonRefundableUpFrontPaymentReceived>
  <us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock contextRef="eol_PE740721--1710-Q0002_STD_31_20150131_0_2025578x2156357_2036820x2089060_2039549x2309240" unitRef="iso4217_USD" decimals="-5" id="id_10801076_9F730D69-4630-4489-8ABF-CA04B4C14AED_2002_4">7500000</us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE740721--1710-Q0002_STD_31_20160731_0_2025578x2398884_2036820x2398883" unitRef="iso4217_USD" decimals="-5" id="id_10801076_8B636FE4-5E71-4A8C-903B-2B9A66E27AA8_1001_0">5000000</us-gaap:ResearchAndDevelopmentExpense>
  <sndx:LicenseAgreementsExpirationPeriod contextRef="eol_PE740721--1710-Q0002_STD_31_20160731_0_2025578x2398884_2036820x2398883" id="id_10801076_5682B65B-8D38-4A34-8705-E796A37CAC5D_1002_3">P10Y</sndx:LicenseAgreementsExpirationPeriod>
  <sndx:UpfrontLicenseFeesPaid contextRef="eol_PE740721--1710-Q0002_STD_31_20070331_0_2025578x2125274_2036820x2089060" unitRef="iso4217_USD" decimals="-5" id="id_10801076_14391EA3-4240-40C7-9279-17B664A30DAF_1001_0">2000000</sndx:UpfrontLicenseFeesPaid>
  <sndx:UpfrontPayments contextRef="eol_PE740721--1710-Q0002_STD_31_20140331_0_2025578x2046871_2036820x2218844" unitRef="iso4217_USD" decimals="0" id="id_10801076_489E939A-211F-4978-828B-9DE70858B6C0_1001_0">695000</sndx:UpfrontPayments>
  <sndx:MilestonePaymentDue contextRef="eol_PE740721--1710-Q0002_STD_31_20140331_0_2025578x2046871_2036820x2218844" unitRef="iso4217_USD" decimals="INF" id="id_10801076_489E939A-211F-4978-828B-9DE70858B6C0_1001_1">1000000</sndx:MilestonePaymentDue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="eol_PE740721--1710-Q0002_STD_31_20160331_0_2040137x2029877" unitRef="iso4217_USD" decimals="-5" id="id_10801076_1A7D9B18-E2E1-4374-9101-8F16C00FE43C_1001_7">4600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="eol_PE740721--1710-Q0002_STD_31_20160331_0_2040137x2029877" unitRef="iso4217_USD" decimals="-5" id="id_10801076_1A7D9B18-E2E1-4374-9101-8F16C00FE43C_1001_2">50500000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="eol_PE740721--1710-Q0002_STD_31_20160331_0_2040137x2029877" unitRef="iso4217_USD" decimals="-5" id="id_10801076_1A7D9B18-E2E1-4374-9101-8F16C00FE43C_1001_4">3100000</us-gaap:PaymentsOfStockIssuanceCosts>
  <sndx:StockBasedCompensationDueToAcceleratedVestingOfStockOptions contextRef="eol_PE740721--1710-Q0002_STD_31_20160331_0_2040137x2029877" unitRef="iso4217_USD" decimals="-5" id="id_10801076_5BEDBFB7-1983-493A-93E2-34D24CFD397B_1002_1">700000</sndx:StockBasedCompensationDueToAcceleratedVestingOfStockOptions>
  <sndx:UnderwritingDiscountsAndCommissions contextRef="eol_PE740721--1710-Q0002_STD_31_20160331_0_2040137x2029877" unitRef="iso4217_USD" decimals="-5" id="id_10801076_1A7D9B18-E2E1-4374-9101-8F16C00FE43C_1001_3">4000000</sndx:UnderwritingDiscountsAndCommissions>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="eol_PE740721--1710-Q0002_STD_31_20160331_0_2040137x2030849" unitRef="shares" decimals="INF" id="id_10801076_1A7D9B18-E2E1-4374-9101-8F16C00FE43C_2001_8">409475</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE740721--1710-Q0002_STD_365_20071231_0_2025578x2125274_2036820x2089060" unitRef="iso4217_USD" decimals="-5" id="id_10801076_14391EA3-4240-40C7-9279-17B664A30DAF_1002_1">2000000</us-gaap:ResearchAndDevelopmentExpense>
  <sndx:PercentageOfSharesIssuableOnConversionOfWarrant contextRef="eol_PE740721--1710-Q0002_STD_366_20161231_0_2025578x2125274_2036820x2089060" unitRef="pure" decimals="4" id="id_10801076_B437BD88-73B3-4512-B71D-74AC55E7F472_1001_0">0.0175</sndx:PercentageOfSharesIssuableOnConversionOfWarrant>
  <sndx:WarrantExpirationTerm contextRef="eol_PE740721--1710-Q0002_STD_366_20161231_0_2025578x2125274_2036820x2089060" id="id_10801076_B437BD88-73B3-4512-B71D-74AC55E7F472_1001_1">P10Y</sndx:WarrantExpirationTerm>
  <dei:EntityRegistrantName contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_2B8770BA-C548-4409-843A-5A64E6BDAD1E_1_1">SYNDAX PHARMACEUTICALS INC</dei:EntityRegistrantName>
  <dei:DocumentType contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_0C11C9DF-831F-42F5-BEED-83091B09470E_1_0">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_2B8770BA-C548-4409-843A-5A64E6BDAD1E_1_2">0001395937</dei:EntityCentralIndexKey>
  <dei:DocumentPeriodEndDate contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_0C11C9DF-831F-42F5-BEED-83091B09470E_1_2">2017-03-31</dei:DocumentPeriodEndDate>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_24">-1488000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:DepreciationAmortizationAndAccretionNet contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_3">6000</us-gaap:DepreciationAmortizationAndAccretionNet>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10801076_4C9A8F9B-9B80-4921-995E-7782EA1C321E_1_4">-0.71</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_34DEB4E7-9454-451B-8596-4666E1D857D3_1_0">&lt;div&gt;
 &lt;p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"&gt;
 In 2011, the Company established a wholly owned subsidiary in the
 United Kingdom. There have been no activities for this entity to
 date. In 2014, the Company established a wholly owned U.S.
 subsidiary, Syndax Securities Corporation. The condensed
 consolidated financial statements include the accounts of the
 Company and its wholly owned subsidiaries. All intercompany
 balances and transactions have been eliminated in
 consolidation.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_2E72E746-4526-419F-8371-2585291916B6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;9. Employee Stock Purchase Plan&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In January 2017, the number of shares of common stock available for
 issuance under the 2015 Employee Stock Purchase Plan (&amp;#x201C;2015
 ESPP&amp;#x201D;), was increased by 182,237 shares as a result of the
 automatic increase provision of the 2015 ESPP. As of March&amp;#xA0;31,
 2017, the total number of shares of common stock available for
 issuance under the 2015 ESPP was 432,237, and no offering periods
 have been approved.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansOtherThanShareBasedCompensationTextBlock>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_21D2BE42-462B-4057-9BD3-E1FA78DA61F6_1_2">1377000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_9DCBEBCF-A44F-4DD0-8467-410B46691087_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;2. Basis of Presentation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company has prepared the accompanying condensed consolidated
 financial statements in conformity with accounting principles
 generally accepted in the United States of America (&amp;#x201C;U.S.
 GAAP&amp;#x201D;). Certain information and footnote disclosures normally
 included in the Company&amp;#x2019;s annual financial statements have
 been condensed or omitted. The interim unaudited condensed
 financial statements have been prepared on the same basis as the
 annual audited financial statements and in the opinion of
 management, reflect all adjustments, which include only normal
 recurring adjustments, necessary for the fair statement of the
 Company&amp;#x2019;s financial position as of March&amp;#xA0;31, 2017, and
 the results of operations, comprehensive loss, and cash flows for
 the three months ended March&amp;#xA0;31, 2017 and 2016. The results
 for the three months ended March&amp;#xA0;31, 2017 are not necessarily
 indicative of the results to be expected for the year ending
 December&amp;#xA0;31, 2017, any other interim periods, or any future
 year or period. These interim financial statements should be read
 in conjunction with the audited financial statements as of and for
 the year ended December&amp;#xA0;31, 2016, and the notes thereto, which
 are included in the Company&amp;#x2019;s Annual Report on&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;Form&amp;#xA0;10-K&lt;/font&gt;&amp;#xA0;that was filed with the
 Securities and Exchange Commission (&amp;#x201C;SEC&amp;#x201D;) on
 March&amp;#xA0;14, 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In 2011, the Company established a wholly owned subsidiary in the
 United Kingdom. There have been no activities for this entity to
 date. In 2014, the Company established a wholly owned U.S.
 subsidiary, Syndax Securities Corporation. The condensed
 consolidated financial statements include the accounts of the
 Company and its wholly owned subsidiaries. All intercompany
 balances and transactions have been eliminated in
 consolidation.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:AvailableForSaleSecuritiesTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_1B9FAF66-BFBF-48BA-8E8A-B1CB30E93ABF_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The following table summarizes the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;available-for-sale&lt;/font&gt;&lt;/font&gt;&amp;#xA0;securities:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="65%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Amortized&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Unrealized&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Unrealized&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Losses&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;u&gt;March&amp;#xA0;31, 2017&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,430&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,451&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Corporate bonds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,001&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(23&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;43,978&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,431&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(23&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,429&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;u&gt;December&amp;#xA0;31, 2016&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,125&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,186&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Corporate bonds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,305&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,300&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,430&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
  <dei:DocumentFiscalYearFocus contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_0C11C9DF-831F-42F5-BEED-83091B09470E_1_3">2017</dei:DocumentFiscalYearFocus>
  <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_5453516C-757C-4BEE-942D-7F4F844FE99C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 A roll-forward of the recurring fair value measurements of the
 common stock warrant liability and the derivative liability
 categorized with Level&amp;#xA0;3 inputs is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Common&amp;#xA0;Stock&lt;br /&gt;
 Warrant&lt;br /&gt;
 Liability&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Derivative&lt;br /&gt;
 Liability&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance &amp;#x2014; December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,848&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;133&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Change in fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,703&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Reclassification&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,551&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(150&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance&amp;#x2014;March 31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;

 &lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
  <dei:AmendmentFlag contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_0C11C9DF-831F-42F5-BEED-83091B09470E_1_1">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_2B8770BA-C548-4409-843A-5A64E6BDAD1E_1_3">--12-31</dei:CurrentFiscalYearEndDate>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_1_5">3930000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_3F5AC4F3-9776-4DA2-B8C4-48BF341AAD2E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;8. Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In January 2017, the number of shares of common stock available for
 issuance under the 2015 Omnibus Incentive Plan (&amp;#x201C;2015
 Plan&amp;#x201D;), was increased by 728,948 shares due to the automatic
 increase provision of the 2015 Plan. As of March&amp;#xA0;31, 2017, the
 total number of shares of common stock available for issuance under
 the 2015 Plan was 1,578,921. The Company recognized stock-based
 compensation expense related to the issuance of stock option awards
 to employees and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employees&lt;/font&gt;&amp;#xA0;in the condensed consolidated
 statements of comprehensive loss as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;223&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,094&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,967&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,377&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,190&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 During the three months ended March&amp;#xA0;31, 2017, the Company
 granted 663,990 stock options to certain executives and employees.
 The grant date fair value of these options was $4.0&amp;#xA0;million,
 or $6.01 per share on a weighted-average basis, and will be
 recognized as compensation expense over the requisite service
 period of three to four years.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 There were 28,200 options exercised during the three months ended
 March&amp;#xA0;31, 2017, resulting in total proceeds of
 $0.1&amp;#xA0;million. The intrinsic value of the options exercised was
 $0.2&amp;#xA0;million. In accordance with the Company&amp;#x2019;s policy,
 the shares were issued from a pool of shares reserved for issuance
 under the 2007 and 2015 Plans.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 As of March&amp;#xA0;31, 2017, there was $10.7&amp;#xA0;million of
 unrecognized compensation cost related to employee and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employee&lt;/font&gt;&amp;#xA0;unvested stock options and
 unvested restricted stock share-based compensation arrangements
 granted under the 2015 and 2007 Plans, which is expected to be
 recognized over a weighted-average remaining service period of 2.8
 years. Stock compensation costs have not been capitalized by the
 Company.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Upon the closing of the IPO on March&amp;#xA0;8, 2016, the vesting of
 certain options granted to two of the Company&amp;#x2019;s executives
 immediately vested, in accordance with their employment agreements.
 The Company recorded $0.7&amp;#xA0;million of additional stock
 compensation expense related to this accelerated vesting in March
 2016.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <dei:DocumentFiscalPeriodFocus contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_0C11C9DF-831F-42F5-BEED-83091B09470E_1_4">Q1</dei:DocumentFiscalPeriodFocus>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_1_16">-13029000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_AE5240EB-0259-4B9C-9DA0-5142D8D16926_1_0">&lt;div&gt;
 &lt;table cellspacing="0" cellpadding="0" width="76%" border="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" align="center"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center" style="border-bottom:1.00pt solid #000000"&gt;
 &lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Short-term deposits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,419&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,630&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Prepaid insurance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;637&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;168&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Interest receivable on short-term investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;210&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;306&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Reimbursable costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;374&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;262&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Prepaid clinical supplies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;310&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;461&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;220&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;202&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr bgcolor="#CCEEFF" style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
 &lt;td valign="top"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"&gt;
 Total prepaid expenses and other current assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,170&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,029&lt;/td&gt;
 &lt;td nowrap="nowrap" valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="font-size:1px;"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
  <dei:EntityFilerCategory contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_2B8770BA-C548-4409-843A-5A64E6BDAD1E_1_4">Non-accelerated Filer</dei:EntityFilerCategory>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="INF" id="id_10801076_3A9DF97D-4214-4B4B-9D83-D3C186E3840B_1_0">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
  <us-gaap:FairValueMeasurementInputsDisclosureTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_F13C8A5F-2A60-4724-90E4-06E14EFEBB85_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;6. Fair Value Measurements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The carrying amounts of cash and cash equivalents, restricted cash,
 accounts payable, and accrued expenses approximated their estimated
 fair values due to the short-term nature of these financial
 instruments. Fair value is defined as the exchange price that would
 be received for an asset or paid to transfer a liability (an exit
 price) in the principal or most advantageous market for the asset
 or liability in an orderly transaction between market participants
 on the measurement date. Valuation techniques used to measure fair
 value are performed in a manner to maximize the use of observable
 inputs and minimize the use of unobservable inputs. The accounting
 standard describes a fair value hierarchy based on three levels of
 inputs, of which the first two are considered observable and the
 last unobservable, that may be used to measure fair value, which
 are the following:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 6pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="100%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="10%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="2%"&gt;&lt;/td&gt;
 &lt;td width="88%"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;i&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Level&amp;#xA0;1&amp;#x2014;&lt;/i&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Quoted prices in active markets that are
 accessible at the market date for identical unrestricted assets or
 liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;i&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Level&amp;#xA0;2&amp;#x2014;&lt;/i&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Inputs other than Level&amp;#xA0;1 that are
 observable, either directly or indirectly, such as quoted prices
 for similar assets or liabilities; quoted prices in markets that
 are not active; or other inputs for which all significant inputs
 are observable or can be corroborated by observable market data for
 substantially the full term of the assets or liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1pt"&gt;
 &lt;td height="8"&gt;&lt;/td&gt;
 &lt;td height="8" colspan="2"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;i&gt;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;&amp;#xA0;Level&amp;#xA0;3&amp;#x2014;&lt;/i&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;Unobservable inputs that are supported by
 little or no market activity and that are significant to the fair
 value of the assets or liabilities.&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 During the periods presented, the Company has not changed the
 manner in which it values assets and liabilities that are measured
 at fair value using Level&amp;#xA0;3 inputs. The Company recognizes
 transfers between levels of the fair value hierarchy as of the end
 of the reporting period. There were no transfers within the
 hierarchy for any of periods presented.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 A summary of the assets and liabilities carried at fair value in
 accordance with the hierarchy defined above is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements
 Using&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Significant&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Prices&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Significant&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;in
 Active&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Observable&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Markets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;u&gt;March&amp;#xA0;31, 2017&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,356&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,910&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,446&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Short-term investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,429&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,429&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92,785&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,910&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,875&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;u&gt;December&amp;#xA0;31, 2016&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23,844&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,089&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Short-term investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105,330&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,089&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;88,241&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Cash equivalents of $18.9&amp;#xA0;million as of March&amp;#xA0;31, 2017
 and $17.1&amp;#xA0;million as of December&amp;#xA0;31, 2016 consisted of
 overnight investments and money market funds and are classified
 within Level&amp;#xA0;1 of the fair value hierarchy because they are
 valued using quoted market prices in active markets. Cash
 equivalents of $3.4&amp;#xA0;million as of March&amp;#xA0;31, 2017 and
 $6.8&amp;#xA0;million as of December&amp;#xA0;31, 2016 consisted of highly
 rated corporate bonds and are classified within Level&amp;#xA0;2 of the
 fair value hierarchy because pricing inputs are other than quoted
 prices in active markets, which are either directly or indirectly
 observable as of the reporting date, and fair value is determined
 through the use of models or other valuation methodologies.
 Short-term investments of $70.4&amp;#xA0;million as of March&amp;#xA0;31,
 2017 and $81.5&amp;#xA0;million as of December&amp;#xA0;31, 2016 consisted
 of commercial paper and highly rated corporate bonds and are
 classified within Level&amp;#xA0;2 of the fair value hierarchy because
 pricing inputs are other than quoted prices in active markets,
 which are either directly or indirectly observable as of the
 reporting date, and fair value is determined through the use of
 models or other valuation methodologies.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The short-term investments are classified as&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;available-for-sale&lt;/font&gt;&lt;/font&gt;&amp;#xA0;securities. As of
 March&amp;#xA0;31, 2017, the remaining contractual maturities of
 the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;available-for-sale&lt;/font&gt;&lt;/font&gt;&amp;#xA0;securities were less than one
 year, and the balance in the Company&amp;#x2019;s accumulated other
 comprehensive loss (income) was comprised solely of activity
 related to the Company&amp;#x2019;s&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;available-for-sale&lt;/font&gt;&lt;/font&gt;&amp;#xA0;securities. There were no
 realized gains or losses recognized on the sale or maturity
 of&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;available-for-sale&lt;/font&gt;&lt;/font&gt;&amp;#xA0;securities during the three
 months ended March&amp;#xA0;31, 2017 and 2016. As a result, the Company
 did not reclassify any amounts out of accumulated other
 comprehensive loss (income) for the same periods. The Company has a
 limited number of&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;available-for-sale&lt;/font&gt;&lt;/font&gt;&amp;#xA0;securities in insignificant
 loss positions as of March&amp;#xA0;31, 2017, which the Company does
 not intend to sell and has concluded it will not be required to
 sell before recovery of the amortized cost for the investment at
 maturity. The following table summarizes the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;available-for-sale&lt;/font&gt;&lt;/font&gt;&amp;#xA0;securities:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="65%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Amortized&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Unrealized&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Unrealized&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Gains&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Losses&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Fair&amp;#xA0;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;u&gt;March&amp;#xA0;31, 2017&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,430&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;26,451&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Corporate bonds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;44,001&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;0&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(23&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;43,978&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,431&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;21&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(23&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,429&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;u&gt;December&amp;#xA0;31, 2016&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Commercial paper&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,125&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;61&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;30,186&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Corporate bonds&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,305&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;51,300&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,430&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;67&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(11&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 A roll-forward of the recurring fair value measurements of the
 common stock warrant liability and the derivative liability
 categorized with Level&amp;#xA0;3 inputs is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="74%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="9%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Common&amp;#xA0;Stock&lt;br /&gt;
 Warrant&lt;br /&gt;
 Liability&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Derivative&lt;br /&gt;
 Liability&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance &amp;#x2014; December&amp;#xA0;31, 2015&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,848&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;133&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Change in fair value&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,703&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Reclassification&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(4,551&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(150&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Balance&amp;#x2014;March 31, 2016&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The common stock warrant liability was recorded at fair value
 determined by using the Black-Scholes option-pricing model. This
 method of valuation involves using inputs such as the fair value of
 the Company&amp;#x2019;s common stock, stock price volatility, the
 contractual term of the warrant, risk-free interest rates, and
 dividend yields. Due to the nature of these inputs, the valuation
 of the warrants was considered a Level&amp;#xA0;3 measurement. Upon the
 closing of the IPO, the warrant was reclassified to
 additional&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt;&amp;#xA0;capital. See Note 5 for
 further discussion of the accounting for the Bayer common stock
 warrant as well as for a summary of the significant inputs and
 assumptions used to determine the fair value of the warrant. The
 derivative liability related to the contingent success fee owed
 under the term loans. Upon the completion of an IPO or upon the
 occurrence of certain change of control or liquidation events, the
 Company was required to pay a $0.2&amp;#xA0;million success fee. The
 Company had recorded the success fee as a derivative financial
 liability. The initial fair value of the derivative of
 $0.1&amp;#xA0;million had been recorded as a debt discount. The term
 loans were paid in full in October 2015; however, the liability for
 the success fee survived the repayment of the term loans. Upon
 completion of the IPO this is no longer accounted for as a
 derivative, and the success fee of $0.2&amp;#xA0;million that was
 payable in June 2018 was included in other long-term liabilities.
 The success fee was paid in full in March 2017.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:FairValueMeasurementInputsDisclosureTextBlock>
  <us-gaap:EarningsPerShareTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_DF0BC689-D9D3-464A-B578-E9EC195B313C_1_0">&lt;div&gt;
 &lt;p&gt;&amp;#xA0;&lt;b&gt;4. Net Loss per Share Attributable to Common
 Stockholders&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Basic net loss per share attributable to common stockholders is
 computed by dividing the net loss attributable to common
 stockholders by the weighted-average number of common shares
 outstanding for the period. Because the Company has reported a net
 loss for all periods presented, diluted net loss per common share
 is the same as basic net loss per common share for those periods.
 The following table summarizes the computation of basic and diluted
 net loss per share attributable to common stockholders of the
 Company:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three Months Ended
 March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands,&amp;#xA0;except&amp;#xA0;share&amp;#xA0;and&amp;#xA0;per&amp;#xA0;share&amp;#xA0;data)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Numerator&amp;#x2014;basic and diluted:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="5"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,971&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,330&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accretion of convertible preferred stock dividends&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,598&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss attributable to common stockholders&amp;#x2014;basic and
 diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,971&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,928&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss per share attributable to common stockholders&amp;#x2014; basic
 and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.71&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Denominator&amp;#x2014;basic and diluted:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted-average common shares used to compute net loss per
 share&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,231,602&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,541,536&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The following potentially dilutive securities have been excluded
 from the computation of diluted weighted-average shares outstanding
 because such securities have an antidilutive impact due to losses
 reported (in common stock equivalent shares):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options to purchase common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,147,793&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,717,539&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Common stock warrant&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;357,840&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;357,840&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Restricted stock subject to future vesting&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,006&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,148&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;

 &lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_1_9">259000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:SalesRevenueNet contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_1_2">305000</us-gaap:SalesRevenueNet>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_1_12">206000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_1_11">-53000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_17">25095000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_689DFEA9-D6ED-4B4B-9E43-AB45E091D511_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 A summary of the assets and liabilities carried at fair value in
 accordance with the hierarchy defined above is as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="92%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="61%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="5%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;Fair Value Measurements
 Using&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Quoted&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Significant&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Prices&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Other&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Significant&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Total&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;in
 Active&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Observable&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;
 &lt;b&gt;Unobservable&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Carrying&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Markets&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Inputs&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(Level 1)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(Level 2)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;(Level 3)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="14" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;u&gt;March&amp;#xA0;31, 2017&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;22,356&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,910&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,446&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Short-term investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,429&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;70,429&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;92,785&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,910&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;73,875&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;&lt;u&gt;December&amp;#xA0;31, 2016&lt;/u&gt;&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Assets:&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Cash equivalents&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;23,844&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,089&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;6,755&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 3em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Short-term investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;81,486&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 5em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;105,330&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;17,089&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;88,241&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_049DD0E1-6C37-4084-A688-2BB07AC2B39C_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;10. Income Taxes&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company has not recorded any net tax provision for the periods
 presented due to the losses incurred and the need for a full
 valuation allowance on net deferred tax assets. The difference
 between the income tax expense at the U.S. federal statutory rate
 and the recorded provision is primarily due to the valuation
 allowance provided on all deferred tax assets.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:LicensesRevenue contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_1_1">305000</us-gaap:LicensesRevenue>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_11">-7000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:OperatingExpenses contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_1_6">13482000</us-gaap:OperatingExpenses>
  <us-gaap:NetIncomeLoss contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_1">-12971000</us-gaap:NetIncomeLoss>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_18">11063000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_9">366000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_8">1141000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_4C9A8F9B-9B80-4921-995E-7782EA1C321E_1_3">-12971000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_8DEA558E-3150-4B26-A676-9BA0BE0AA997_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Recently Issued and Adopted Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In November 2016, the Financial Accounting Standards Board
 (&amp;#x201C;FASB&amp;#x201D;) issued Accounting Standards Update
 (&amp;#x201C;ASU&amp;#x201D;) ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-18,&lt;/font&gt;&amp;#xA0;&lt;i&gt;&amp;#x201C;Statement of Cash
 Flows (Topic 230): Restricted Cash&amp;#x201D;&lt;/i&gt;&amp;#xA0;(&amp;#x201C;ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-18&amp;#x201D;).&lt;/font&gt;&amp;#xA0;ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-18&lt;/font&gt;&amp;#xA0;requires that restricted cash
 and restricted cash equivalents be included with cash and cash
 equivalents when reconciling the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;beginning-of-period&lt;/font&gt;&lt;/font&gt;&amp;#xA0;and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;end-of-period&lt;/font&gt;&lt;/font&gt;&amp;#xA0;total amounts shown on the
 statement of cash flows. The statement of cash flows must also
 explain the change during the period in the total of cash, cash
 equivalents, and restricted cash or restricted cash
 equivalents.&amp;#xA0;ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-18&lt;/font&gt;&amp;#xA0;will be effective for the
 Company on January&amp;#xA0;1, 2018. The Company does not expect the
 adoption of this standard to have a material impact on its
 consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In March 2016, the FASB issued ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-09,&lt;/font&gt;&amp;#xA0;&lt;i&gt;Compensation&amp;#x2014;Stock
 Compensation (Topic 718): Improvements to Employee Share-Based
 Payment Accounting&lt;/i&gt;&amp;#xA0;(&amp;#x201C;ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-09&amp;#x201D;).&lt;/font&gt;&amp;#xA0;ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-09&lt;/font&gt;&amp;#xA0;simplifies several aspects
 related to the accounting for share-based payment transactions,
 including the accounting for income taxes, forfeitures, statutory
 tax withholding requirements and classification on the statement of
 cash flows. The Company adopted ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-09&lt;/font&gt;&amp;#xA0;on January&amp;#xA0;1, 2017, and
 it did not have a material impact on its condensed consolidated
 balance sheet, condensed consolidated statement of comprehensive
 loss and condensed statement of cash flows. As part of the adoption
 of this guidance, the Company adopted a policy to account for
 forfeitures as they occur.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In February 2016, the FASB issued ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-02,&lt;/font&gt;&amp;#xA0;&amp;#x201C;&lt;i&gt;Leases (Topic
 842)&lt;/i&gt;.&amp;#x201D; Under ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-02,&lt;/font&gt;&amp;#xA0;lessees will be required to
 recognize, for all leases of 12 months or more, a liability to make
 lease payments and a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;right-of-use&lt;/font&gt;&lt;/font&gt;&amp;#xA0;asset representing the right
 to use the underlying asset for the lease term. Additionally, the
 guidance requires improved disclosures to help users of financial
 statements better understand the nature of an entity&amp;#x2019;s
 leasing activities. This ASU is effective for public reporting
 companies for interim and annual periods beginning after
 December&amp;#xA0;15, 2018, with early adoption permitted, and must be
 adopted using a modified retrospective approach. The standard will
 be effective for the Company on January&amp;#xA0;1, 2019. The Company
 is in the process of evaluating the effect of the new guidance on
 the Company&amp;#x2019;s consolidated financial statements and related
 disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In May 2014, the FASB issued ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09,&lt;/font&gt;&amp;#xA0;&lt;i&gt;Revenue from Contracts with
 Customers&amp;#xA0;&lt;/i&gt;(&amp;#x201C;ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&amp;#x201D;).&lt;/font&gt;&amp;#xA0;ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt;&amp;#xA0;supersedes the revenue
 recognition requirements of FASB Accounting Standards Codification
 (&amp;#x201C;ASC&amp;#x201D;) Topic 605,&amp;#xA0;&lt;i&gt;Revenue
 Recognition&amp;#xA0;&lt;/i&gt;and
 most industry-specific guidance throughout the Accounting Standards
 Codification, resulting in the creation of FASB ASC Topic
 606,&amp;#xA0;&lt;i&gt;Revenue
 from Contracts with Customers&lt;/i&gt;. ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt;&amp;#xA0;requires entities to recognize
 revenue in a way that depicts the transfer of promised goods or
 services to customers in an amount that reflects the consideration
 to which the entity expects to be entitled to in exchange for those
 goods or services. Adoption will be permitted using either a
 retrospective or modified retrospective approach. In July 2015,
 FASB voted to delay the effective date of the standard by one year
 to the first quarter of 2018 to provide companies sufficient time
 to implement the standard. Early adoption will be permitted. The
 Company is currently evaluating the method by which it will
 implement this standard and the impact of the adoption of this
 standard on the Company&amp;#x2019;s consolidated financial
 statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_1_7">-13177000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_23">117000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_1_15">-58000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherCurrentAssetsTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_85FDB970-72A7-47A3-9A42-28DEB066FE78_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;7. Prepaid Expenses and Other Current Assets&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="66%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="12%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;March&amp;#xA0;31,&amp;#xA0;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;December&amp;#xA0;31,&amp;#xA0;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Short-term deposits&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,419&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,630&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid insurance&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;637&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;168&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Interest receivable on short-term investments&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;210&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;306&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Reimbursable costs&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;374&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;262&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Prepaid clinical supplies&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;310&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;461&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Other&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;220&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;202&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total prepaid expenses and other current assets&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,170&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,029&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;

 &lt;/div&gt;</us-gaap:OtherCurrentAssetsTextBlock>
  <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_16">14081000</us-gaap:PaymentsToAcquireShortTermInvestments>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_10">-305000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="INF" id="id_10801076_3B663E5B-ED21-4EF6-A5C2-3DA9A4E6F184_1_0">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NatureOfOperations contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_A30B48D5-3E95-4CEB-8ACE-1255D8C761C6_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;1. Nature of Business&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Syndax Pharmaceuticals, Inc. (the Company) is a clinical stage
 biopharmaceutical company developing an innovative pipeline of
 combination therapies in multiple cancer indications. The
 Company&amp;#x2019;s lead product candidate, entinostat, is currently
 being evaluated in a Phase 3 clinical trial for advanced hormone
 receptor positive, human epidermal growth factor receptor 2
 negative breast cancer. Entinostat was granted Breakthrough Therapy
 designation by the U.S. Food and Drug Administration following
 positive results from the Company&amp;#x2019;s Phase 2b clinical trial,
 ENCORE 301. The Company is developing entinostat, which has direct
 effects on both cancer cells and immune regulatory cells, and
 SNDX-6352, a monoclonal antibody that targets the colony
 stimulating&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;factor-1&lt;/font&gt;&amp;#xA0;receptor to enhance the
 body&amp;#x2019;s immune response on tumors that have shown sensitivity
 to immunotherapy. Given its potential ability to block the function
 of immune suppressive cells in the tumor microenvironment, the
 Company is evaluating entinostat as a combination therapeutic in
 Phase 1b/2 clinical trials with Merck&amp;#xA0;&amp;amp; Co., Inc.
 for&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-small&lt;/font&gt;&amp;#xA0;cell lung cancer and melanoma;
 with Genentech, Inc. for triple negative breast cancer; and with
 Merck KGaA, Darmstadt, Germany, and Pfizer Inc. for ovarian cancer.
 The Company is evaluating SNDX-6352 in a single ascending dose
 Phase 1 clinical trial. In April 2017, a fourth cohort for
 microsatellite stable colorectal cancer was added to the Phase 1b/2
 clinical trial with Merck&amp;#xA0;&amp;amp; Co., Inc. The Company plans to
 continue to leverage the technical and business expertise of our
 management team and scientific collaborators to license, acquire
 and develop additional cancer therapies to expand our pipeline.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In March 2016, the Company completed its initial public offering
 (&amp;#x201C;IPO&amp;#x201D;) whereby it sold 4,809,475 shares of common
 stock at the initial public offering price of $12.00 per share,
 which included 409,475 shares issued pursuant to the
 underwriters&amp;#x2019; partial exercise of their over-allotment option
 to purchase additional shares of common stock. The aggregate net
 proceeds received by the Company from the offering were
 $50.5&amp;#xA0;million, net of underwriting discounts and commissions
 of $4.0&amp;#xA0;million and offering expenses of $3.1&amp;#xA0;million.
 Upon the closing of the IPO, all outstanding shares of the
 Company&amp;#x2019;s outstanding convertible preferred stock converted
 into 12,872,551 shares of common stock; and the Company&amp;#x2019;s
 outstanding warrant liability to purchase 357,840 shares of the
 Company&amp;#x2019;s common stock valued at $4.6&amp;#xA0;million was
 reclassified to additional&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt;&amp;#xA0;capital. In connection with
 the closing of the Company&amp;#x2019;s IPO, the Company filed an
 amended and restated certificate of incorporation and adopted
 amended and restated bylaws, both of which were approved by the
 Company&amp;#x2019;s board of directors and stockholders on
 September&amp;#xA0;28, 2015 and February&amp;#xA0;24, 2016, respectively.
 Pursuant to the amended and restated certificate of incorporation,
 the Company is now authorized to issue 100,000,000 shares of common
 stock and 10,000,000 shares of preferred stock.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Since its inception, the Company has devoted its efforts
 principally to research and development and raising capital. The
 Company is subject to risks common to companies in the development
 stage, including, but not limited to, successful development of
 therapeutics, obtaining additional funding, protection of
 proprietary therapeutics, compliance with government regulations,
 fluctuations in operating results, dependence on key personnel and
 collaborative partners, and risks associated with industry changes.
 The Company&amp;#x2019;s long-term success is dependent upon its ability
 to successfully develop and market its product candidates, expand
 its oncology drug pipeline, earn revenue, obtain additional capital
 when needed, and ultimately, achieve profitable operations. The
 Company anticipates that it will be several years before either
 entinostat or SNDX-6352 is approved, if ever, and the Company
 begins to generate revenue from sales of entinostat and SNDX-6352.
 Accordingly, management expects to incur substantial losses on the
 ongoing development of entinostat and SNDX-6352 and does not expect
 to achieve positive cash flow from operations for the foreseeable
 future, if ever. As a result, the Company will continue to require
 additional capital to move forward with its business plan. While
 certain amounts of this additional capital were raised in the past,
 there can be no assurance that funds necessary beyond these amounts
 will be available in amounts or on terms sufficient to ensure
 ongoing operations.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company&amp;#x2019;s management believes that the cash, cash
 equivalents and short-term investments balances as of
 March&amp;#xA0;31, 2017 should enable the Company to maintain its
 planned operations for at least the next 12&amp;#xA0;months. The
 Company&amp;#x2019;s ability to fund all of its planned operations
 internally beyond that date, including the completion of its
 ongoing and planned clinical trial activities, may be substantially
 dependent upon whether the Company can obtain sufficient funding on
 terms acceptable to the Company. Proceeds from additional capital
 transactions would allow the Company to accelerate and/or expand
 its planned research and development activities. In the event that
 sufficient funds were not available, the Company may be required to
 delay or reduce expenditures to conserve cash, which could involve
 scaling back or curtailing development and general and
 administrative activities.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:NatureOfOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_12">-12668000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:OtherNoncashIncomeExpense contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_6">-7000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_15">-49000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="shares" decimals="INF" id="id_10801076_82AE5FC5-D68D-46CD-A628-9C916B29A28B_1_0">28200</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:UseOfEstimates contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_4F35D7E3-7B7B-4F2E-A867-FA1EEF849B8A_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The preparation of condensed consolidated financial statements in
 conformity with U.S. GAAP requires management to make estimates and
 assumptions that affect the reported amounts of assets and
 liabilities and the disclosure of contingent assets and liabilities
 at the date of the condensed consolidated financial statements and
 the reported amounts of costs and expenses during the reporting
 period. The Company bases estimates and assumptions on historical
 experience when available and on various factors that it believes
 to be reasonable under the circumstances. The Company evaluates its
 estimates and assumptions on an ongoing basis. The Company&amp;#x2019;s
 actual results may differ from these estimates under different
 assumptions or conditions.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_D2FEC2DB-E1F1-4C3A-9435-25515643A123_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 0pt; TEXT-INDENT: 4%"&gt;
 The following potentially dilutive securities have been excluded
 from the computation of diluted weighted-average shares outstanding
 because such securities have an antidilutive impact due to losses
 reported (in common stock equivalent shares):&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="76%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="3%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Options to purchase common stock&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;3,147,793&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,717,539&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Common stock warrant&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;357,840&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;357,840&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Restricted stock subject to future vesting&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;7,006&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;13,148&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_7CDAD74C-2AB9-4906-BE1F-8D06DAC76A73_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"&gt;
 The following table summarizes the computation of basic and diluted
 net loss per share attributable to common stockholders of the
 Company:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; BORDER-COLLAPSE: collapse" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="72%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="7%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;Three Months Ended
 March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: #000000 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;(In&amp;#xA0;thousands,&amp;#xA0;except&amp;#xA0;share&amp;#xA0;and&amp;#xA0;per&amp;#xA0;share&amp;#xA0;data)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Numerator&amp;#x2014;basic and diluted:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom" colspan="5"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,971&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(10,330&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Accretion of convertible preferred stock dividends&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap" align="right"&gt;
 &amp;#x2014;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2,598&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss attributable to common stockholders&amp;#x2014;basic and
 diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,971&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(12,928&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Net loss per share attributable to common stockholders&amp;#x2014;basic
 and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(0.71&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;(2.85&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;)&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 &lt;b&gt;Denominator&amp;#x2014;basic and diluted:&lt;/b&gt;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; PAGE-BREAK-INSIDE: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Weighted-average common shares used to compute net loss per
 share&amp;#x2014;basic and diluted&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;18,231,602&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;4,541,536&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: #000000 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_652A13B2-23D5-463C-B966-29F9C4D99DAD_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company recognized stock-based compensation expense related to
 the issuance of stock option awards to employees and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-employees&lt;/font&gt;&amp;#xA0;in the condensed consolidated
 statements of comprehensive loss as follows:&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 12pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;table style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WORD-SPACING: 0px; BORDER-COLLAPSE: collapse; TEXT-TRANSFORM: none; ORPHANS: 2; WIDOWS: 2; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px" cellspacing="0" cellpadding="0" width="76%" align="center" border="0"&gt;
 &lt;tr&gt;
 &lt;td width="78%"&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td valign="bottom" width="6%"&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;td&gt;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="6" align="center"&gt;
 &lt;b&gt;Three&amp;#xA0;Months&amp;#xA0;Ended&amp;#xA0;March&amp;#xA0;31,&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2017&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td style="BORDER-BOTTOM: rgb(0,0,0) 1pt solid" valign="bottom" colspan="2" align="center"&gt;&lt;b&gt;2016&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 8pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" colspan="6" align="center"&gt;&lt;b&gt;(In
 thousands)&lt;/b&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Research and development&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;283&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;223&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 General and administrative&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,094&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,967&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 1px solid; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; break-inside: avoid" bgcolor="#CCEEFF"&gt;
 &lt;td valign="top"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; MARGIN-LEFT: 1em; MARGIN-TOP: 0pt; TEXT-INDENT: -1em"&gt;
 Total&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;1,377&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;$&lt;/td&gt;
 &lt;td valign="bottom" align="right"&gt;2,190&lt;/td&gt;
 &lt;td valign="bottom" nowrap="nowrap"&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr style="FONT-SIZE: 1px"&gt;
 &lt;td valign="bottom"&gt;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;&amp;#xA0;&amp;#xA0;&lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td valign="bottom"&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; BORDER-TOP: rgb(0,0,0) 3px double; MARGIN-TOP: 0pt"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;/td&gt;
 &lt;td&gt;&amp;#xA0;&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/table&gt;
 &lt;br class="Apple-interchange-newline" /&gt;

 &lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_BDA43B63-8E6C-4CE3-9C02-D0D06828FB8E_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;3. Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Significant Accounting Policies&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company&amp;#x2019;s&amp;#xA0;significant accounting policies are
 disclosed in the audited consolidated financial statements for the
 year ended December&amp;#xA0;31, 2016 and the notes thereto, which are
 included in the Company&amp;#x2019;s Annual Report on&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;Form&amp;#xA0;10-K&lt;/font&gt;&amp;#xA0;that was filed with the SEC on
 March&amp;#xA0;14, 2017, have had no material changes during the three
 months ended March&amp;#xA0;31, 2017.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The preparation of condensed consolidated financial statements in
 conformity with U.S. GAAP requires management to make estimates and
 assumptions that affect the reported amounts of assets and
 liabilities and the disclosure of contingent assets and liabilities
 at the date of the condensed consolidated financial statements and
 the reported amounts of costs and expenses during the reporting
 period. The Company bases estimates and assumptions on historical
 experience when available and on various factors that it believes
 to be reasonable under the circumstances. The Company evaluates its
 estimates and assumptions on an ongoing basis. The Company&amp;#x2019;s
 actual results may differ from these estimates under different
 assumptions or conditions.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Other Assets&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Other assets consist of deferred issuance costs, long-term security
 deposits and noncurrent restricted cash. Deferred issuance costs
 consist primarily of direct incremental legal and accounting fees
 relating to the IPO and other public offerings, which are deferred
 until completion of the offering, at which time they are
 reclassified to additional&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt;&amp;#xA0;capital as a reduction of the
 offering proceeds. In the event that the offering is terminated,
 all costs deferred will be expensed immediately. As of
 March&amp;#xA0;31, 2017 and 2016, the Company had capitalized deferred
 issuance costs of $0.1&amp;#xA0;million and $0. The capitalized
 deferred issuance costs as of March&amp;#xA0;31, 2017 related to the at
 the market equity offering.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Research and Development&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In instances where the Company has entered into cost-sharing
 arrangements, all research and development costs reimbursed by the
 collaborators are accounted for as reductions to research and
 development expense. For the three months ended March&amp;#xA0;31, 2017
 and 2016, the Company incurred $0.4&amp;#xA0;million and $0,
 respectively, in external costs related to cost-sharing
 collaborations, of which $0.2&amp;#xA0;million and $0 has been recorded
 as a reduction to research and development expense,
 respectively.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Recently Issued and Adopted Accounting Pronouncements&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In November 2016, the Financial Accounting Standards Board
 (&amp;#x201C;FASB&amp;#x201D;) issued Accounting Standards Update
 (&amp;#x201C;ASU&amp;#x201D;) ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-18,&lt;/font&gt;&amp;#xA0;&lt;i&gt;&amp;#x201C;Statement of Cash
 Flows (Topic 230): Restricted Cash&amp;#x201D;&lt;/i&gt;&amp;#xA0;(&amp;#x201C;ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-18&amp;#x201D;).&lt;/font&gt;&amp;#xA0;ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-18&lt;/font&gt;&amp;#xA0;requires that restricted cash
 and restricted cash equivalents be included with cash and cash
 equivalents when reconciling the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;beginning-of-period&lt;/font&gt;&lt;/font&gt;&amp;#xA0;and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;end-of-period&lt;/font&gt;&lt;/font&gt;&amp;#xA0;total amounts shown on the
 statement of cash flows. The statement of cash flows must also
 explain the change during the period in the total of cash, cash
 equivalents, and restricted cash or restricted cash
 equivalents.&amp;#xA0;ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-18&lt;/font&gt;&amp;#xA0;will be effective for the
 Company on January&amp;#xA0;1, 2018. The Company does not expect the
 adoption of this standard to have a material impact on its
 consolidated financial statements.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In March 2016, the FASB issued ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-09,&lt;/font&gt;&amp;#xA0;&lt;i&gt;Compensation&amp;#x2014;Stock
 Compensation (Topic 718): Improvements to Employee Share-Based
 Payment Accounting&lt;/i&gt;&amp;#xA0;(&amp;#x201C;ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-09&amp;#x201D;).&lt;/font&gt;&amp;#xA0;ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-09&lt;/font&gt;&amp;#xA0;simplifies several aspects
 related to the accounting for share-based payment transactions,
 including the accounting for income taxes, forfeitures, statutory
 tax withholding requirements and classification on the statement of
 cash flows. The Company adopted ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-09&lt;/font&gt;&amp;#xA0;on January&amp;#xA0;1, 2017, and
 it did not have a material impact on its condensed consolidated
 balance sheet, condensed consolidated statement of comprehensive
 loss and condensed statement of cash flows. As part of the adoption
 of this guidance, the Company adopted a policy to account for
 forfeitures as they occur.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &amp;#xA0;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In February 2016, the FASB issued ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-02,&lt;/font&gt;&amp;#xA0;&amp;#x201C;&lt;i&gt;Leases (Topic
 842)&lt;/i&gt;.&amp;#x201D; Under ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2016-02,&lt;/font&gt;&amp;#xA0;lessees will be required to
 recognize, for all leases of 12 months or more, a liability to make
 lease payments and a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;right-of-use&lt;/font&gt;&lt;/font&gt;&amp;#xA0;asset representing the right
 to use the underlying asset for the lease term. Additionally, the
 guidance requires improved disclosures to help users of financial
 statements better understand the nature of an entity&amp;#x2019;s
 leasing activities. This ASU is effective for public reporting
 companies for interim and annual periods beginning after
 December&amp;#xA0;15, 2018, with early adoption permitted, and must be
 adopted using a modified retrospective approach. The standard will
 be effective for the Company on January&amp;#xA0;1, 2019. The Company
 is in the process of evaluating the effect of the new guidance on
 the Company&amp;#x2019;s consolidated financial statements and related
 disclosures.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In May 2014, the FASB issued ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09,&lt;/font&gt;&amp;#xA0;&lt;i&gt;Revenue from Contracts with
 Customers&amp;#xA0;&lt;/i&gt;(&amp;#x201C;ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&amp;#x201D;).&lt;/font&gt;&amp;#xA0;ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt;&amp;#xA0;supersedes the revenue
 recognition requirements of FASB Accounting Standards Codification
 (&amp;#x201C;ASC&amp;#x201D;) Topic 605,&amp;#xA0;&lt;i&gt;Revenue
 Recognition&amp;#xA0;&lt;/i&gt;and
 most industry-specific guidance throughout the Accounting Standards
 Codification, resulting in the creation of FASB ASC Topic
 606,&amp;#xA0;&lt;i&gt;Revenue
 from Contracts with Customers&lt;/i&gt;. ASU&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;2014-09&lt;/font&gt;&amp;#xA0;requires entities to recognize
 revenue in a way that depicts the transfer of promised goods or
 services to customers in an amount that reflects the consideration
 to which the entity expects to be entitled to in exchange for those
 goods or services. Adoption will be permitted using either a
 retrospective or modified retrospective approach. In July 2015,
 FASB voted to delay the effective date of the standard by one year
 to the first quarter of 2018 to provide companies sufficient time
 to implement the standard. Early adoption will be permitted. The
 Company is currently evaluating the method by which it will
 implement this standard and the impact of the adoption of this
 standard on the Company&amp;#x2019;s consolidated financial
 statements.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <dei:TradingSymbol contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_2B8770BA-C548-4409-843A-5A64E6BDAD1E_1_0">SNDX</dei:TradingSymbol>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_1_4">9552000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_D172CB19-87BB-46C0-AF79-EB10EF32E036_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Research and Development&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In instances where the Company has entered into cost-sharing
 arrangements, all research and development costs reimbursed by the
 collaborators are accounted for as reductions to research and
 development expense. For the three months ended March&amp;#xA0;31, 2017
 and 2016, the Company incurred $0.4&amp;#xA0;million and $0,
 respectively, in external costs related to cost-sharing
 collaborations, of which $0.2&amp;#xA0;million and $0 has been recorded
 as a reduction to research and development expense,
 respectively.&lt;/p&gt;
 &lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_21">118000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-5" id="id_10801076_82AE5FC5-D68D-46CD-A628-9C916B29A28B_1_2">200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_22">-1000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_4">1377000</us-gaap:ShareBasedCompensation>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="shares" decimals="0" id="id_10801076_4C9A8F9B-9B80-4921-995E-7782EA1C321E_1_6">18231602</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_4FA05135-0AE4-456C-A786-0A9E94322C46_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;11. Related-Party Transactions&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company&amp;#x2019;s chief executive officer and member of the board
 of directors is also a managing director at MPM Asset Management,
 LLC, which holds an investment in the Company&amp;#x2019;s common
 stock.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_3B889BC4-EA38-4933-B026-354F4E06806F_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;12. Subsequent Event&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 On April&amp;#xA0;6, 2017, the Company entered into a sales agreement
 with Cowen and Company, LLC (&amp;#x201C;Cowen&amp;#x201D;) under which the
 Company may issue and sell shares of its common stock having
 aggregate sales proceeds of up to $50.0&amp;#xA0;million from time to
 time through Cowen, acting as agent, in a series of one or more at
 the market equity offerings. Cowen is not required to sell any
 specific amount, but acts as the Company&amp;#x2019;s sales agent using
 commercially reasonable efforts consistent with its normal trading
 and sales practices. Shares sold pursuant to the sales agreement
 will be sold pursuant to a shelf registration statement, which
 became effective on April&amp;#xA0;20, 2017. The Company&amp;#x2019;s common
 stock will be sold at prevailing market prices at the time of the
 sale; and as a result, prices may vary. The Company will pay Cowen
 up to 3% of the gross proceeds from any common stock sold through
 the sales agreement. Unless otherwise terminated earlier, the sales
 agreement continues until all shares available under the sales
 agreement have been sold. The proceeds from the offerings, if any,
 will be used for general corporate purposes, including expenditures
 for research and development of the Company&amp;#x2019;s drug products.
 There were no sales under this facility through May&amp;#xA0;5,
 2017.&lt;/p&gt;


 &lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <sndx:SignificantAccountingPoliciesPolicyTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_A108CBB3-5B33-40CD-94B7-147D19A29117_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Significant Accounting Policies&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company&amp;#x2019;s&amp;#xA0;significant accounting policies are
 disclosed in the audited consolidated financial statements for the
 year ended December&amp;#xA0;31, 2016 and the notes thereto, which are
 included in the Company&amp;#x2019;s Annual Report on&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;Form&amp;#xA0;10-K&lt;/font&gt;&amp;#xA0;that was filed with the SEC on
 March&amp;#xA0;14, 2017, have had no material changes during the three
 months ended March&amp;#xA0;31, 2017.&lt;/p&gt;


 &lt;/div&gt;</sndx:SignificantAccountingPoliciesPolicyTextBlock>
  <sndx:VestingOfRestrictedStockValue contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_31">11000</sndx:VestingOfRestrictedStockValue>
  <sndx:OtherAssetsPolicyTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_EE55D7A6-7C58-4A0E-82A4-8B73E51024DA_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;i&gt;Other Assets&lt;/i&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Other assets consist of deferred issuance costs, long-term security
 deposits and noncurrent restricted cash. Deferred issuance costs
 consist primarily of direct incremental legal and accounting fees
 relating to the IPO and other public offerings, which are deferred
 until completion of the offering, at which time they are
 reclassified to additional&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt;&amp;#xA0;capital as a reduction of the
 offering proceeds. In the event that the offering is terminated,
 all costs deferred will be expensed immediately. As of
 March&amp;#xA0;31, 2017 and 2016, the Company had capitalized deferred
 issuance costs of $0.1&amp;#xA0;million and $0. The capitalized
 deferred issuance costs as of March&amp;#xA0;31, 2017 related to the at
 the market equity offering.&lt;/p&gt;
 &lt;/div&gt;</sndx:OtherAssetsPolicyTextBlock>
  <sndx:SignificantAgreementsDisclosureTextBlock contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" id="id_10801076_C0400E46-2C75-403D-B671-D82DC721D11D_1_0">&lt;div&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;5. Significant Agreements&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;UCB Biopharma Sprl&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 8%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In July 2016, the Company entered into a license agreement (the
 &amp;#x201C;UCB License Agreement&amp;#x201D;) with UCB Biopharma Sprl
 (&amp;#x201C;UCB&amp;#x201D;), under which UCB granted to the Company a
 worldwide, sublicenseable, exclusive license to UCB6352, which the
 Company refers to as SNDX-6352, an&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;IND-ready&lt;/font&gt;&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;anti-CSF-1R&lt;/font&gt;&lt;/font&gt;&amp;#xA0;monoclonal antibody.&amp;#xA0;The
 Company made a nonrefundable upfront payment of $5.0&amp;#xA0;million
 to UCB in the third quarter of 2016.&amp;#xA0;Additionally, subject to
 the achievement of certain milestone events, the Company may be
 required to pay UCB up to $119.5&amp;#xA0;million in&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;one-time&lt;/font&gt;&amp;#xA0;development and regulatory
 milestone payments over the term of the UCB License
 Agreement.&amp;#xA0;In the event that the Company or any of its
 affiliates or sublicensees commercializes SNDX-6352, the Company
 will also be obligated to pay UCB low double-digit royalties on
 sales, subject to reduction in certain circumstances, as well as up
 to an aggregate of $250.0&amp;#xA0;million in potential&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;one-time,&lt;/font&gt;&amp;#xA0;sales-based milestone payments
 based on achievement of certain annual sales thresholds.&amp;#xA0;Under
 certain circumstances, the Company may be required to share a
 percentage of&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-royalty&lt;/font&gt;&amp;#xA0;income from sublicensees,
 subject to certain deductions, with UCB.&amp;#xA0;The Company is solely
 responsible for the development and commercialization of SNDX-6352,
 except that UCB is performing a limited set of transitional
 chemistry, manufacturing and control tasks related to
 SNDX-6352.&amp;#xA0;Each party may terminate the UCB License Agreement
 for the other party&amp;#x2019;s uncured material breach or insolvency;
 and the Company may terminate the UCB License Agreement at will at
 any time upon advance written notice to UCB. UCB may terminate the
 UCB License Agreement if the Company or any of its affiliates or
 sublicensees institutes a legal challenge to the validity,
 enforceability, or patentability of the licensed patent
 rights.&amp;#xA0;Unless terminated earlier in accordance with its
 terms, the UCB License Agreement will continue on a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;country-by-country&lt;/font&gt;&lt;/font&gt;&amp;#xA0;and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;product-by-product&lt;/font&gt;&lt;/font&gt;&amp;#xA0;basis until the later of:
 (i)&amp;#xA0;the expiration of all of the licensed patent rights in
 such country; (ii)&amp;#xA0;the expiration of all regulatory
 exclusivity applicable to the product in such country; and
 (iii)&amp;#xA0;10 years from the date of the first commercial sale of
 the product in such country. As of the date of the UCB License
 Agreement, the asset acquired had no alternative future use nor had
 it reached a stage of technological feasibility. As the processes
 or activities that were acquired along with the license do not
 constitute a &amp;#x201C;business,&amp;#x201D; the transaction has been
 accounted for as an asset acquisition.&amp;#xA0;As a result of these
 findings, the upfront payment of $5.0&amp;#xA0;million has been
 recorded as research and development expense in the consolidated
 statement of comprehensive loss.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Kyowa Hakko Kirin Co., Ltd.&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 On December&amp;#xA0;19, 2014 (the &amp;#x201C;Effective Date&amp;#x201D;), the
 Company entered into a license agreement (the &amp;#x201C;KHK License
 Agreement&amp;#x201D;) with Kyowa Hakko Kirin Co., Ltd.
 (&amp;#x201C;KHK&amp;#x201D;), under which the Company granted KHK an
 exclusive license to develop and commercialize entinostat in Japan
 and Korea. Under the terms of the KHK License Agreement, the
 Company will be responsible for the manufacture and supply of the
 products during the development activities. In addition to the
 license and manufacturing obligations, the Company is obligated to
 provide KHK access to&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;know-how&lt;/font&gt;&amp;#xA0;and regulatory information the
 Company may develop over the life of the entinostat patent. Lastly,
 to the extent additional intellectual property is developed during
 the term of the agreement, KHK will receive the right to the
 intellectual property when and if available. KHK will conduct the
 development, regulatory approval filings, and commercialization
 activities of entinostat in Japan and Korea. KHK paid the Company
 $25.0&amp;#xA0;million upfront, which included a $7.5&amp;#xA0;million
 equity investment of 536,049 shares of Series&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;B-1&lt;/font&gt;&amp;#xA0;convertible preferred stock
 and a $17.5&amp;#xA0;million&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-refundable&lt;/font&gt;&amp;#xA0;cash payment. In addition, to
 the extent certain development and commercial milestones are
 achieved, KHK will be required to pay the Company up to
 $75.0&amp;#xA0;million in milestone payments over the term of the
 license agreement. The term of the agreement commenced on the
 Effective Date and, unless earlier terminated in accordance with
 the terms of the agreement, will continue on a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;country-by-country&lt;/font&gt;&lt;/font&gt;&amp;#xA0;and&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;&lt;font style="WHITE-SPACE: nowrap"&gt;product-by-product&lt;/font&gt;&lt;/font&gt;&amp;#xA0;basis, until the later of:
 (i)&amp;#xA0;the date all valid claims of the last effective patent
 among the Company&amp;#x2019;s patents expires or is abandoned,
 withheld, or is otherwise invalidated in such country; and
 (ii)&amp;#xA0;15 years from the date of the first commercial sale of a
 product in the Japan or Korea.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The purchase of the Series&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;B-1&lt;/font&gt;&amp;#xA0;and the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;up-front&lt;/font&gt;&amp;#xA0;payment of the license fee
 were accounted for separately. The Company allocated the amount of
 consideration related to Series&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;B-1&lt;/font&gt;&amp;#xA0;equal to the fair value of the
 Series&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;B-1&lt;/font&gt;&amp;#xA0;shares on the Effective Date
 based on a share price of $14.39 per share, which resulted in
 $7.7&amp;#xA0;million of proceeds allocated to the Series&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;B-1&lt;/font&gt;&amp;#xA0;and the remaining
 consideration of $17.3&amp;#xA0;million allocated to the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;up-front&lt;/font&gt;&amp;#xA0;license fee. The fair value of
 the Series&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;B-1&lt;/font&gt;&amp;#xA0;of $14.39 per share was based
 on a contemporaneous valuation. The Company received
 $7.5&amp;#xA0;million and issued the Series&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;B-1&lt;/font&gt;&amp;#xA0;in January 2015 and received
 the remaining $17.5&amp;#xA0;million in February 2015. On the date of
 issuance, the Company recorded accretion of $5.4&amp;#xA0;million to
 record the Series&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;B-1&lt;/font&gt;&amp;#xA0;at its redemption value.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company has concluded that this agreement is within the scope
 of ASC&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;605-25,&lt;/font&gt;&amp;#xA0;&lt;i&gt;Revenue Recognition,
 Multiple-Element Arrangements&lt;/i&gt;. Pursuant to this guidance, the
 Company identified the following deliverables: (i)&amp;#xA0;licenses,
 (ii)&amp;#xA0;clinical supply and manufacturing obligations,
 (iii)&amp;#xA0;rights to access and use materials and data, and
 (iv)&amp;#xA0;rights to additional intellectual property. All other
 potential deliverables included in the arrangement have been deemed
 either contingent or inconsequential or perfunctory, individually
 and in the aggregate. Moreover, the Company has evaluated all
 deliverables included in the KHK License Agreement and determined
 that there are two units of accounting in connection with its
 obligations at inception under the KHK License Agreement:
 (i)&amp;#xA0;license unit of accounting and (ii)&amp;#xA0;rights to
 additional intellectual property. The first three deliverables
 identified above comprise the license unit of accounting. The
 Company concluded that the stand-alone selling price for the rights
 to additional intellectual property unit of account is immaterial.
 As such, the entire $17.3&amp;#xA0;million allocated to the upfront
 payment was allocated to the license unit of accounting.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The arrangement consideration allocated to the license unit of
 accounting will be recognized as revenue ratably over the
 Company&amp;#x2019;s expected services period (currently expected to be
 through 2029) commencing on the date of the first delivery of the
 clinical trial materials. In June 2015, the Company began
 delivering clinical materials to KHK and commenced recognizing
 revenue from the upfront consideration of $17.3&amp;#xA0;million.
 During the three months ended March&amp;#xA0;31, 2017 and 2016, the
 Company recognized $0.3&amp;#xA0;million of revenue associated with the
 KHK License Agreement. As of March&amp;#xA0;31, 2017, there was
 $15.1&amp;#xA0;million of deferred revenue related to the KHK License
 Agreement, which is classified as current or long-term in the
 consolidated balance sheets.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In October 2016, the Company entered into a clinical
 trial&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;co-funding&lt;/font&gt;&amp;#xA0;agreement with KHK under which
 the Company will expand its clinical trial agreement with Eastern
 Cooperative Oncology Group (the &amp;#x201C;ECOG Agreement&amp;#x201D;) to
 include enrollments from sites in Korea.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 14pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Eastern Cooperative Oncology Group&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In March 2014, the Company entered into the ECOG Agreement with
 Eastern Cooperative Oncology Group, a contracting entity for the
 Eastern Cooperative Oncology Group&amp;#x2014;American College of
 Radiology Imaging Network Cancer Research Group
 (&amp;#x201C;ECOG-ACRIN&amp;#x201D;), that describes the parties&amp;#x2019;
 obligations with respect to the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;NCI-sponsored&lt;/font&gt;&amp;#xA0;pivotal Phase 3 clinical trial
 of entinostat. Under the terms of the ECOG Agreement, ECOG-ACRIN
 will perform this clinical trial in accordance with the clinical
 trial protocol and a mutually agreed scope of work. The Company
 will provide a fixed level of financial support for the clinical
 trial through an upfront payment of $695,000 and a series of
 payments of up to $1.0&amp;#xA0;million each that are comprised of
 milestone payments through the completion of enrollment and
 time-based payments through the completion of patient monitoring
 post-enrollment. In addition, the Company is obligated to supply
 entinostat and placebo to ECOG-ACRIN for use in the clinical trial.
 During the second quarter of 2016, the ECOG Agreement was amended
 to provide additional study activities and the contractual
 obligation increased by $0.8&amp;#xA0;million. During the first quarter
 of 2017, the ECOG Agreement was amended to expand the study to
 include enrollments from sites in Korea and to provide additional
 study activities and the contractual obligation increased by
 $2.0&amp;#xA0;million. As of March&amp;#xA0;31, 2017, the Company&amp;#x2019;s
 aggregate payment obligations under this agreement were
 approximately $23.4&amp;#xA0;million; and its remaining payment
 obligations are approximately $14.9&amp;#xA0;million over an estimated
 period of approximately four years.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 Data and inventions from the Phase 3 clinical trial are owned by
 ECOG-ACRIN. The Company has access to the data generated in the
 clinical trial, both directly from ECOG-ACRIN under the ECOG
 Agreement as well as from the NCI. Additionally, ECOG-ACRIN has
 granted the Company a&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;non-exclusive&lt;/font&gt;&amp;#xA0;royalty-free license to any
 inventions or discoveries that are derived from entinostat as a
 result of its use during the clinical trial, along with a first
 right to negotiate an exclusive license to any of these inventions
 or discoveries. Either party may terminate the ECOG Agreement in
 the event of an uncured material breach by the other party or if
 the U.S. Food and Drug Administration (&amp;#x201C;FDA&amp;#x201D;) or
 National Cancer Institute (&amp;#x201C;NCI&amp;#x201D;) withdraws the
 authorization to perform the clinical trial in the United States.
 The parties may jointly terminate the ECOG Agreement if the parties
 agree that safety-related issues support termination of the
 clinical trial.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 8pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 The Company records the appropriate clinical trial expenses in its
 financial statements by matching those expenses with the period in
 which the services and efforts are expended. The Company accounts
 for these expenses according to the progress of the clinical trial
 as measured by patient enrollment and the timing of various aspects
 of the clinical trial. The Company determines accrual estimates
 through financial models, taking into account discussion with
 applicable personnel and ECOG-ACRIN as to the progress or state of
 consummation of the clinical trial or the services completed.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; MARGIN-LEFT: 75px; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 14pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 &lt;b&gt;Bayer Pharma AG (formerly known as Bayer Schering Pharma
 AG)&lt;/b&gt;&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In March 2007, the Company entered into a license agreement (the
 &amp;#x201C;Bayer Agreement&amp;#x201D;) with Bayer Schering Pharma AG
 (&amp;#x201C;Bayer&amp;#x201D;) for a worldwide, exclusive license to develop
 and commercialize entinostat and any other products containing the
 same active ingredient. Under the terms of the Bayer Agreement, the
 Company paid a nonrefundable upfront license fee of
 $2.0&amp;#xA0;million and is responsible for the development and
 marketing of entinostat. The Company recorded the $2.0&amp;#xA0;million
 license fee as research and development expense during the year
 ended December&amp;#xA0;31, 2007, as it had no alternative future use.
 The Company will pay Bayer royalties on a sliding scale based on
 net sales, if any, and make future milestone payments to Bayer of
 up to $150.0&amp;#xA0;million in the event that certain specified
 development and regulatory goals and sales levels are achieved. In
 June 2014, a development milestone was achieved, and the Company
 recorded $2.0&amp;#xA0;million of research and development expense,
 which has been fully paid.&lt;/p&gt;
 &lt;p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: &amp;quot;Times New Roman&amp;quot;; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 4%; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px"&gt;
 In connection with the Bayer Agreement, the Company issued to Bayer
 a warrant to purchase the number of shares of the Company&amp;#x2019;s
 common stock equal to 1.75% of the shares of common stock
 outstanding on a fully diluted basis as of the earlier of the date
 the warrant is exercised or the closing of the IPO. The warrant
 contains anti-dilution protection to maintain Bayer&amp;#x2019;s
 potential ownership at 1.75% of the shares of common stock
 outstanding on a fully diluted basis, which requires that the
 actual number of shares of common stock issuable pursuant to the
 warrant be increased or decreased for any changes in the fully
 diluted shares of common stock outstanding. The warrant is
 exercisable at an exercise price of $1.54 per share and expires
 upon the earlier of the&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;10-year&lt;/font&gt;&amp;#xA0;anniversary of the closing of
 the IPO or the date of the consummation of a disposition
 transaction. The warrant was classified as a long-term liability
 and recorded at fair value with the changes in the fair value
 recorded in other expense. The Company used the Black-Scholes
 option-pricing model to determine the fair value of the warrant.
 Upon the closing of the IPO, the anti-dilution protection for the
 warrant expired, resulting in the reclassification of the warrant
 liability to additional&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;paid-in&lt;/font&gt;&amp;#xA0;capital. The warrant
 was&amp;#xA0;&lt;font style="WHITE-SPACE: nowrap"&gt;re-measured&lt;/font&gt;&amp;#xA0;using current assumptions just
 prior to the reclassification.&lt;/p&gt;


 &lt;/div&gt;</sndx:SignificantAgreementsDisclosureTextBlock>
  <sndx:IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_1_30">135000</sndx:IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0_2021628x2022619" unitRef="shares" decimals="0" id="id_10801076_7B851873-3F10-49CB-9024-ED71ECE86F42_1001_0">3147793</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0_2021628x2039180" unitRef="shares" decimals="0" id="id_10801076_7B851873-3F10-49CB-9024-ED71ECE86F42_2001_1">357840</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0_2021628x2041099" unitRef="shares" decimals="0" id="id_10801076_7B851873-3F10-49CB-9024-ED71ECE86F42_3001_2">7006</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0_2022410x2022419_2026789x2263464" unitRef="iso4217_USD" decimals="-3" id="id_10801076_2686C1B3-CB33-4DA4-BA82-268874340CB9_5001_2">-1703000</us-gaap:FairValueAdjustmentOfWarrants>
  <sndx:ReclassificationOfCommonStockWarrantLiabilityToAdditionalPaidInCapital contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0_2022410x2022419_2026789x2263464" unitRef="iso4217_USD" decimals="-3" id="id_10801076_2686C1B3-CB33-4DA4-BA82-268874340CB9_5001_3">-4551000</sndx:ReclassificationOfCommonStockWarrantLiabilityToAdditionalPaidInCapital>
  <sndx:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityReclassificationToEquity contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0_2022410x2022419_2027829x2026079" unitRef="iso4217_USD" decimals="-3" id="id_10801076_464B2606-0840-4D5E-AEB8-E159A5822F1A_5001_3">150000</sndx:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityReclassificationToEquity>
  <sndx:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0_2022410x2022419_2027829x2026079" unitRef="iso4217_USD" decimals="-3" id="id_10801076_464B2606-0840-4D5E-AEB8-E159A5822F1A_5001_2">17000</sndx:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityChangeInFairValue>
  <sndx:ContractualObligationsTerm contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0_2025578x2046871_2036820x2218844" id="id_10801076_AE3C9D1C-1B02-415E-992B-9DC830F05A7C_1001_3">P4Y</sndx:ContractualObligationsTerm>
  <sndx:IncreaseDecreaseInContractualObligation contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0_2025578x2046871_2036820x2218844" unitRef="iso4217_USD" decimals="-5" id="id_10801076_AE3C9D1C-1B02-415E-992B-9DC830F05A7C_1001_0">2000000</sndx:IncreaseDecreaseInContractualObligation>
  <us-gaap:RecognitionOfDeferredRevenue contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0_2025578x2156357_2036820x2089060" unitRef="iso4217_USD" decimals="-5" id="id_10801076_425221EA-975B-4628-BF90-44D7B870EBED_1001_0">300000</us-gaap:RecognitionOfDeferredRevenue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0_2029102x2154578" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10801076_D7AFB00B-A93C-445D-920B-30D4029EBA1E_1001_2">6.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0_2029102x2154578" unitRef="shares" decimals="INF" id="id_10801076_D7AFB00B-A93C-445D-920B-30D4029EBA1E_1001_0">663990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <sndx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionGrantDateFairValue contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0_2029102x2154578" unitRef="iso4217_USD" decimals="-5" id="id_10801076_D7AFB00B-A93C-445D-920B-30D4029EBA1E_1001_1">4000000</sndx:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockOptionGrantDateFairValue>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0_2029102x2429960" id="id_10801076_188E48DE-CC04-459A-B7A7-D2079E484E8B_1001_1">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0_2029841x2029413" unitRef="iso4217_USD" decimals="-3" id="id_10801076_21D2BE42-462B-4057-9BD3-E1FA78DA61F6_1001_1">1094000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0_2029841x2035076" unitRef="iso4217_USD" decimals="-3" id="id_10801076_21D2BE42-462B-4057-9BD3-E1FA78DA61F6_2001_0">283000</us-gaap:AllocatedShareBasedCompensationExpense>
  <sndx:IncreaseDecreaseInResearchAndDevelopmentExpense contextRef="eol_PE740721--1710-Q0002_STD_90_20170331_0_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_10801076_3B52685B-79CF-420E-BFEC-4842EDA8C109_1001_1">-200000</sndx:IncreaseDecreaseInResearchAndDevelopmentExpense>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_24">8000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:DepreciationAmortizationAndAccretionNet contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_3">53000</us-gaap:DepreciationAmortizationAndAccretionNet>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD_per_shares" decimals="2" id="id_10801076_4C9A8F9B-9B80-4921-995E-7782EA1C321E_2_4">-2.85</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:ConversionOfStockAmountConverted1 contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_33">328942000</us-gaap:ConversionOfStockAmountConverted1>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_21D2BE42-462B-4057-9BD3-E1FA78DA61F6_2_2">2190000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_28">73000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_2_5">4272000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:ComprehensiveIncomeNetOfTax contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_2_16">-10130000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:FairValueAdjustmentOfWarrants contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_2_10">1703000</us-gaap:FairValueAdjustmentOfWarrants>
  <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_2_9">144000</us-gaap:InterestIncomeExpenseNonoperatingNet>
  <us-gaap:SalesRevenueNet contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_2_2">305000</us-gaap:SalesRevenueNet>
  <us-gaap:NonoperatingIncomeExpense contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_2_12">-1577000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OtherNonoperatingIncomeExpense contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_2_11">-18000</us-gaap:OtherNonoperatingIncomeExpense>
  <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_17">31857000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
  <us-gaap:LicensesRevenue contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_2_1">305000</us-gaap:LicensesRevenue>
  <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_11">1285000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
  <us-gaap:OperatingExpenses contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_2_6">9058000</us-gaap:OperatingExpenses>
  <us-gaap:NetIncomeLoss contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_1">-10330000</us-gaap:NetIncomeLoss>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_18">-47137000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_9">-403000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_8">613000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_4C9A8F9B-9B80-4921-995E-7782EA1C321E_2_3">-12928000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:OperatingIncomeLoss contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_2_7">-8753000</us-gaap:OperatingIncomeLoss>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_23">53548000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_2_15">200000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:PaymentsToAcquireShortTermInvestments contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_16">78863000</us-gaap:PaymentsToAcquireShortTermInvestments>
  <us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_10">-305000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncomeTaxExpenseBenefit contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="INF" id="id_10801076_3B663E5B-ED21-4EF6-A5C2-3DA9A4E6F184_2_0">0</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_12">-6403000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_14">133000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:IncreaseDecreaseInRestrictedCash contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_15">-2000</us-gaap:IncreaseDecreaseInRestrictedCash>
  <us-gaap:TemporaryEquityDividendsAdjustment contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_29">2598000</us-gaap:TemporaryEquityDividendsAdjustment>
  <us-gaap:ProceedsFromIssuanceInitialPublicOffering contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_20">53549000</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_16CD1380-46DC-4001-976D-738D4C64F255_2_4">4786000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_22">-1000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
  <us-gaap:ShareBasedCompensation contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_4">2190000</us-gaap:ShareBasedCompensation>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="shares" decimals="0" id="id_10801076_4C9A8F9B-9B80-4921-995E-7782EA1C321E_2_6">4541536</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <sndx:FairValueAdjustmentOfWarrantsAndDerivativeLiabilities contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_5">-1720000</sndx:FairValueAdjustmentOfWarrantsAndDerivativeLiabilities>
  <sndx:VestingOfRestrictedStockValue contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_31">10000</sndx:VestingOfRestrictedStockValue>
  <sndx:ReclassificationOfCommonStockWarrantLiabilityToAdditionalPaidInCapital contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_32">4551000</sndx:ReclassificationOfCommonStockWarrantLiabilityToAdditionalPaidInCapital>
  <sndx:IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0" unitRef="iso4217_USD" decimals="-3" id="id_10801076_F8742DEE-F42B-4BFD-95CD-D188E0496EC5_2_30">1400000</sndx:IssuanceCostsIncludedInAccountsPayableAndAccruedExpenses>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0_2021628x2022619" unitRef="shares" decimals="0" id="id_10801076_7B851873-3F10-49CB-9024-ED71ECE86F42_1002_0">2717539</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0_2021628x2039180" unitRef="shares" decimals="0" id="id_10801076_7B851873-3F10-49CB-9024-ED71ECE86F42_2002_1">357840</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0_2021628x2041099" unitRef="shares" decimals="0" id="id_10801076_7B851873-3F10-49CB-9024-ED71ECE86F42_3002_2">13148</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:RecognitionOfDeferredRevenue contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0_2025578x2156357_2036820x2089060" unitRef="iso4217_USD" decimals="-5" id="id_10801076_425221EA-975B-4628-BF90-44D7B870EBED_1002_0">300000</us-gaap:RecognitionOfDeferredRevenue>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0_2029841x2029413" unitRef="iso4217_USD" decimals="-3" id="id_10801076_21D2BE42-462B-4057-9BD3-E1FA78DA61F6_1002_1">1967000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0_2029841x2035076" unitRef="iso4217_USD" decimals="-3" id="id_10801076_21D2BE42-462B-4057-9BD3-E1FA78DA61F6_2002_0">223000</us-gaap:AllocatedShareBasedCompensationExpense>
  <sndx:IncreaseDecreaseInResearchAndDevelopmentExpense contextRef="eol_PE740721--1710-Q0002_STD_91_20160331_0_2036820x2025359" unitRef="iso4217_USD" decimals="-5" id="id_10801076_3B52685B-79CF-420E-BFEC-4842EDA8C109_1002_1">0</sndx:IncreaseDecreaseInResearchAndDevelopmentExpense>
  <sndx:IncreaseDecreaseInContractualObligation contextRef="eol_PE740721--1710-Q0002_STD_91_20160630_0_2025578x2046871_2036820x2218844" unitRef="iso4217_USD" decimals="-5" id="id_10801076_489E939A-211F-4978-828B-9DE70858B6C0_1002_2">800000</sndx:IncreaseDecreaseInContractualObligation>
  <sndx:UpfrontPayments contextRef="eol_PE740721--1710-Q0002_STD_92_20160930_0_2025578x2398884_2036820x2398883" unitRef="iso4217_USD" decimals="-5" id="id_10801076_5682B65B-8D38-4A34-8705-E796A37CAC5D_1001_0">5000000</sndx:UpfrontPayments>
  <context id="eol_PE740721--1710-Q0002_STD_92_20160930_0_2025578x2398884_2036820x2398883">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:UCBBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:UcbLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_91_20160630_0_2025578x2046871_2036820x2218844">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:EasternCooperativeOncologyGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:ClinicalTrialMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_91_20160331_0_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_91_20160331_0_2029841x2035076">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_91_20160331_0_2029841x2029413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_91_20160331_0_2025578x2156357_2036820x2089060">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:KyowaHakkoKirinCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_91_20160331_0_2021628x2041099">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_91_20160331_0_2021628x2039180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_91_20160331_0_2021628x2022619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_91_20160331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_90_20170331_0_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_90_20170331_0_2029841x2035076">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_90_20170331_0_2029841x2029413">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_90_20170331_0_2029102x2429960">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_90_20170331_0_2029102x2154578">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandAndSevenStockIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_90_20170331_0_2025578x2156357_2036820x2089060">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:KyowaHakkoKirinCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_90_20170331_0_2025578x2046871_2036820x2218844">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:EasternCooperativeOncologyGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:ClinicalTrialMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_90_20170331_0_2022410x2022419_2027829x2026079">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_90_20170331_0_2022410x2022419_2026789x2263464">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sndx:CommonStockWarrantLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_90_20170331_0_2021628x2041099">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_90_20170331_0_2021628x2039180">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_90_20170331_0_2021628x2022619">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_90_20170331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_366_20161231_0_2025578x2125274_2036820x2089060">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:BayerPharmaAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_365_20071231_0_2025578x2125274_2036820x2089060">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:BayerPharmaAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_31_20160331_0_2040137x2030849">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:OverAllotmentOptionMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-03-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_31_20160331_0_2040137x2029877">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-03-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_31_20140331_0_2025578x2046871_2036820x2218844">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:EasternCooperativeOncologyGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:ClinicalTrialMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-03-01</startDate>
      <endDate>2014-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_31_20070331_0_2025578x2125274_2036820x2089060">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:BayerPharmaAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2007-03-01</startDate>
      <endDate>2007-03-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_31_20160731_0_2025578x2398884_2036820x2398883">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:UCBBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:UcbLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-07-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_31_20150131_0_2025578x2156357_2036820x2089060_2039549x2309240">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:KyowaHakkoKirinCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sndx:SeriesBOnePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-01-31</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_28_20150228_0_2025578x2156357_2036820x2089060">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:KyowaHakkoKirinCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2015-02-01</startDate>
      <endDate>2015-02-28</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_27_20140630_0_2025578x2125274_2036820x2089060">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:BayerPharmaAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-06-04</startDate>
      <endDate>2014-06-30</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_1_20170406_0_2033330x2370882_2037362x2039759_2039870x2428472">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">sndx:CowenAndCompanyLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">sndx:AtTheMarketEquityOfferingSalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-04-06</startDate>
      <endDate>2017-04-06</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_1_20170308_0_2040137x2029877">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-03-08</startDate>
      <endDate>2017-03-08</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_1_20170505_0_2037362x2039759">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2017-05-05</startDate>
      <endDate>2017-05-05</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_1_20141219_0_2025578x2156357_2036820x2089060">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:KyowaHakkoKirinCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <startDate>2014-12-19</startDate>
      <endDate>2014-12-19</endDate>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20161231_0_2031210x2026209">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20161231_0_2031210x2024283">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20161231_0_2025578x2125274_2036820x2089060">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:BayerPharmaAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022642x2026006">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022410x2026970_2025340x2428344">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sndx:OvernightInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022410x2026970">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022410x2022419_2027829x2026079">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">us-gaap:DerivativeFinancialInstrumentsLiabilitiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022410x2022419_2026789x2263464">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">sndx:CommonStockWarrantLiabilityMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022410x2021995_2031210x2323317">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">sndx:CorporateBondsAndCommercialPaperMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022410x2021995_2031210x2024283">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20161231_0_2022410x2021995">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20161231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20151231_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170331_0_2040137x2029877">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170331_0_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170331_0_2031210x2026209">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170331_0_2031210x2024283">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170331_0_2029102x2429960">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandSevenAndTwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170331_0_2029102x2256568">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandFifteenOmnibusIncentivePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170331_0_2029102x2084902">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170331_0_2025578x2156357_2036820x2089060">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:KyowaHakkoKirinCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170331_0_2025578x2046871_2036820x2218844">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:EasternCooperativeOncologyGroupMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:ClinicalTrialMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170331_0_2023370x2394104_2033594x2167040_2040137x2029877">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">sndx:SuccessFeePayableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sndx:TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170331_0_2022642x2026006">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170331_0_2022410x2026970_2025340x2428344">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">sndx:OvernightInvestmentsAndMoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170331_0_2022410x2026970">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170331_0_2022410x2021995_2031210x2323317">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">sndx:CorporateBondsAndCommercialPaperMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170331_0_2022410x2021995_2031210x2024283">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170331_0_2022410x2021995">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
    </entity>
    <period>
      <instant>2017-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20160331_0_2040137x2029877">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20160331_0_2036820x2025359">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20160331_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
    </entity>
    <period>
      <instant>2016-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20070331_0_2025578x2125274_2028497x2033371_2036820x2089060">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:BayerPharmaAgMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2007-03-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170505_0_2037362x2039759">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-05-05</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170502_0">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
    </entity>
    <period>
      <instant>2017-05-02</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170131_0_2029102x2084902">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandFifteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-01-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20170131_0_2028497x2033371_2029102x2256568">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sndx:TwoThousandFifteenOmnibusIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2017-01-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20160731_0_2025578x2398884_2036820x2398883">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:UCBBiopharmaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:UcbLicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2016-07-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20151031_0_2033594x2167040">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">sndx:TermLoanMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-10-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20150131_0_2025578x2156357_2036820x2089060_2039549x2309240">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:KyowaHakkoKirinCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sndx:SeriesBOnePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2015-01-31</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20141219_0_2025578x2156357_2036820x2089060_2039549x2309240">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:KyowaHakkoKirinCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">sndx:SeriesBOnePreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-19</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20141219_0_2025578x2156357_2036820x2089060">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:KyowaHakkoKirinCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-19</instant>
    </period>
  </context>
  <context id="eol_PE740721--1710-Q0002_STD_0_20141219_0_2025578x2156357_2028497x2033371_2036820x2089060">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001395937</identifier>
      <segment><xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sndx:KyowaHakkoKirinCoLtdMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">sndx:LicenseAgreementMember</xbrldi:explicitMember></segment>
    </entity>
    <period>
      <instant>2014-12-19</instant>
    </period>
  </context>
  <unit id="iso4217_USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="shares">
    <measure>shares</measure>
  </unit>
  <unit id="iso4217_USD_per_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>pure</measure>
  </unit>
  <unit id="Executives">
    <measure>sndx:Executives</measure>
  </unit>
</xbrl>